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Norsk sammendrag: 
 
 
Heksylaminolevulinat fotodynamisk behandling av kreftcellelinjer. 
 
 
 
Fotodynamisk terapi (PDT) er en behandlingsmetode som kan brukes på både kreft og 
pre-kreft. Metoden er allerede i bruk på klinikker og flere pasienter ved 
hudavdelingen her på St.Olav blir behandlet med PDT hver uke. Metoden er en 
tostegsbehandling der det først enten blir tilsatt en fotosensitizer eller en forløper til 
en fotosensitizer. Fotosensitizer vil i hovedsak akkumuleres i kreftvev og den gjør 
cellene sensitive for vanlig synlig lys. Etter at kreftvevet har blitt lyssensitivt påføres 
det lys med tilpasset bølgelengde. Dette er som regel rødt lys. 
 
Selv om PDT er i bruk på klinikker er det et behov for optimalisering og større 
kunnskap om de effekter metoden gir. Vi har valgt å studere heksylaminolevulinat 
(HAL) basert PDT på cellenivå. Denne varianten av PDT er godkjent for diagnose av 
blærekreft og den aktive fotosensitizeren er protoporfyrin IX (PpIX). I denne 
avhandlingen har vi sett på effektene fra ulike parametere i lyset og fokusert på 
hvilken type celledød som blir indusert samt effekter på proteiner. 
 
Fra de fire studiene i avhandlingen har vi funnet ut at HAL-PDT med rødlys effektivt 
dreper rotteblærekreft-celler, hovedsakelig gjennom nekrose og at fraksjonering av 
lysdosen med 45 sekunder lys etterfulgt av 60 sekund mørke ikke gir endret utslag på 
hverken mengde celledød eller type i forhold til sammenhengende belysning. 
 
Videre så har vi sett at effekter fra HAL-PDT er avhengig av hvilken cellelinje som er 
i bruk. Alle de fem cellelinjenes dose- responskurver varierte både i form og 
lysdoseområde. Vi så også at lav lysintensitet ikke var like effektiv som høy 
lysintensitet for sub-letale doser og vi fikk resultater som indikerer at lav lysintensitet 
induserer apoptose i større grad enn PDT med høy lysintensitet. PpIX kan aktiveres av 
både rødt og blått lys, men det ser ut til at rødlys HAL-PDT gir mer apoptose enn 
blålys HAL-PDT. 
 
I de to siste studiene var fokuset på proteinendringer. Blålys HAL-PDT på 
rotteblærekreftceller viste at det ble indusert post-translasjonelle modifikasjoner, noen 
proteiner endret mengde og at en del proteiner ble karbonylerte etter HAL-PDT.  
 
I den siste studien viste vi at økt lysdose gir økt induksjon av reaktive oksygen arter 
(ROS). Vi identifiserte over 1900 proteiner som var reversibelt oksidert på cystein 
sete, i stor grad som følge av ROS. Ut fra disse studerte vi en undergruppe som vi var 
ekstra sikre på at var endret som følge av HAL-PDT. Over halvparten av disse viste 
seg å være assosiert med programmert celledød og flere av disse er igjen kjent for å 
være redoksregulert. Redoksregulering av proteiner er et voksende fagfelt og 
mekanismens betydning i cellers signalverden øker. For å verifisere at noen av de 
proteinene vi identifiserte kan være en sentral triggermekanisme for HAL-PDT 
indusert apoptose behøves det en del mer forskning. 
Oppsummert så bidrar denne avhandlingen til en bedre forståelse av effektene etter 
HAL-PDT og den peker på viktigheten av å bruke optimale parametere for selve 
belysningen og den åpner for at reversibel oksidering av cystein seter kan være en 
sentral mekanisme for indusering av apoptose etter HAL-PDT. 
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Background 
 
This background is subdivided into three main topics: photodynamic therapy (PDT), 
cell death and oxidative stress. Each subject is large, diverse and integrated with each 
other. Hopefully the separation into topics makes the introduction of this thesis easier to 
comprehend.  PDT is the method used in this thesis and will be described in general 
terms first and then more detailed on the most relevant topics for this thesis.  Cell death 
and oxidative stress are both important effects of PDT and have been aspects of this 
thesis. 
 
1.1 Photodynamic therapy (PDT) 
 
Photodynamic therapy is a form of cancer treatment based on light activation of a 
photo-sensitive compound, a photosensitizer (PS). This treatment is approved for 
clinical use with different photosensitizers in several countries for different types of 
tumour malignant and non-malignant conditions.  
 
1.1.1 PDT in general 
 
Several different photosensitizers have been tested for PDT and some of them have been 
approved for clinical use. Two main features of a photosensitizer are that it absorbs light 
within the visible range and that it accumulates preferably in cancerous cells/tissue. A 
good PS has a high ratio for entering a long-lived excited state after light absorption, has 
high cancer to normal tissue ratio and quite rapid clearance from the organism. The first 
step in PDT is to administer a PS or a PS precursor; the second step is to illuminate the 
target with appropriate light. These two steps results in oxidative stress at the cellular 
level which can induce cell death. When dealing with the subject PDT it is important to 
know that there are some differences between effects in vivo and in vitro, as well as at 
organism and cellular levels, respectively. In vivo treatment is much more complex 
since PDT will induce an inflammatory response and vascular shut down in addition to 
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direct target kill.  PDT will be described in more detail in the subsequent paragraphs. 
 
1.1.1.1 History of PDT 
 
The history of PDT has been well reviewed by others and only a brief account will be 
given here (Agostinis et al., 2011; Dolmans et al., 2003; Honigsmann, 2013; Krammer 
& Plaetzer, 2008; Moan & Peng, 2003).  It started 3000 years ago as phototherapy when 
the Indians, the Egyptians and the Chinese applied light alone on humans for therapeutic 
purposes. Phototherapy was used to treat diverse disorders such as psoriasis, vitiligo and 
skin cancer. In 1903 Niels Finsen was awarded the Nobel Prize for his use of light in 
treatment of lupus vulgaris and was accordingly acknowledged as the founder of 
modern phototherapy. The combination of photoactive components and light to treat a 
disorder was first described in one of India’s sacred books 1400 BC. Both Indians and 
Egyptians treated vitiligo by natural psoralens in combination with solar light.  
Further progress did not occur until 1974 when PUVA (treatment with psoralens 
and UVA light) was reported to be an efficient psoriasis treatment. Around 1900, 
researchers observed that the combination of certain chemicals and light in the visible 
range could induce cell death. Oscar Raab and his supervisor Hermann von Tappeiner 
carried out ground-breaking work and this group introduced the term photodynamic in 
1907.  In 1913, Friedrich Meyer-Betz injected himself with hematoporphyrin (HPD) 
and became light sensitive for over two months; this was the first time 
hematoporphyrins were used on humans. Hans Fischer received the Nobel Prize in 1930 
for his work on porphyrins. Porphyrin-induced fluorescence from tumours was first 
observed and published by Albert Policard in 1924.  HPD was partially purified and 
sold under the trade name Photofrin which became a widely used photosensitizer for 
clinical PDT.   
A major breakthrough for PDT came in 1975 when Dougherty and co-workers 
reported that combination of HPD and red light reduced tumour in mice (Dougherty et 
al., 1975). In the same year Kelly and co-workers reported elimination of bladder cancer 
in mice after treatment with HPD and light and in 1976 this group started the first 
human trial with HPD to treat bladder cancer (Kelly, 1975; Kelly et al., 1975).  Due to 
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the impurity of HPD and the long lasting light sensitivity when using Photofrin an 
intensive search for better photosensitizers was undertaken. In 1979, Zvi Malik and co-
workers published a paper describing how aminolevulinate (ALA) increases 
endogenous production of protoporphyrin IX (PpIX) constituting the basis for ALA-
based PDT, but without the light part of PDT (Malik & Djaldetti, 1979; Malik et al., 
1979).   
Two years later Kennedy and Pottier started to study ALA-induced porphyrin 
production and in 1987 they treated the first patient with ALA-PDT (Kennedy & Pottier, 
1992; Kennedy et al., 1990; Pottier et al., 1986). After these publications several other 
researchers began to study the basics and possible application of ALA in PDT.  In 1993 
PDT was for the first time approved as cancer treatment, when Photofrin-based PDT 
was approved as treatment against bladder cancer in Canada. At the present, several 
photosensitizers are clinically approved, see Table 1.  
 
1.1.1.2 Mechanisms of PDT; photochemical reaction 
 
There are three essential components in PDT: photosensitizer (PS), light and molecular 
oxygen. None of the components is toxic alone, but when combined appropriately they 
can together initiate a photochemical reaction which can generate oxidative stress and 
cause toxicity and cell death. PDT is a two-step procedure. After administration of a PS 
the tumour locus is irradiated with light of appropriate wavelength. In the subsequent 
text phototoxicity and the photochemical reaction will be described. 
   
9 
 
 
 
Figure 1: A Jablonski diagram. For details, see text below. Adapted from (Dai et al., 2012) 
 
The Jablonski diagram in Figure 1 is often used as an illustration of the interaction of 
light with molecules, the photophysical processes.  A photosensitizer in the ground state 
is in a singlet state configuration. In the singlet state the molecule is characterized by 
paired electrons. Electrons can only have two orientations; +1/2 and -½ (often denoted  
DV³VSLQXS´DQG³VSLQGRZQ´ĹDQGĻDQGSDLUHGHOHFWURQVDUHLQDntiparallel direction 
and thus have a total spin quantum number S=0, and a magnetic quantum number of 1, 
M=2S + 1. Ground state is the preferred energetic state for a molecule and in ground 
state, S0, all the electrons are in their energetically lowest possible orbital. When a PS 
absorbs a light quantum of appropriate energy (wavelength) one of its electrons shifts to 
a higher energetic level Sx (where x = 0, 1, 2, 3… and denotes the level of increased 
energetic state).  Since all excited states are energetically less preferable than the ground 
state, the PS will return to S0 after a short time period (typically 10-15-10-12 second 
(Plaetzer et al., 2008)). The de-excitation of a molecule can take place in several ways. 
All excited energetic states Sx are sub-sectioned into several vibrational levels 
and an electron in a high vibrational level of an excited state will rapidly return to the 
energetically lowest level of that state through vibrational relaxation. The excess energy 
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in vibrational relaxation is lost as heat. If the PS was in Sx where x ޓ1 it can after 
vibrational relaxation drop to the first excited singlet state, S1.  
The relaxation from S1 to S0 can take place in three different ways: emission of a photon 
(fluorescence), heat radiation or by crossing into a triplet state and further interact with 
other molecules. Fluorescence will always occur from the lowest vibrational state in S1 
and is therefore not dependent on the wavelength of the absorbed light, the photon has a 
fixed wavelength, and the emitted photon has always lower energy (wavelength) than 
the absorbed one (Plaetzer et al., 2009).   
The third possibility for relaxation is when the PS crosses from S1 into an 
isoenergetic level of the triplet state, T1. In triplet state the electrons are unpaired and 
have thus S = 1 and M =3. The crossing from S1 to T1 is spin-forbidden and is a non-
radiative process called inter system crossing, ISC. Most PSs have a high quantum yield 
for this process. Triplet states are generally characterized with a relative long lifetime, 
up to seconds. De-excitation from T1 takes place either by a radiative process called 
phosphorescence or by a photochemical reaction. The effects of PDT come from 
photochemical reactions. 
 
The term phototoxicity is used for the process where a non-toxic compound is converted 
into an oxidant or produces an oxidant after absorption of light. Phototoxicity can be 
separated into two main photochemical reactions; type I and type II. These 
photochemical reactions are the starting points for the effects of PDT and therefore 
optimal PSs have a high yield for triplet excited state and photochemical reactions. 
Type I photochemical reaction is when the PS de-excites from T1 to ground state 
by transferring electrons (or protons) to oxygen or other nearby molecules. This result in 
radical anions (or cations, respectively) and these radicals are likely to react with 
molecular oxygen to form reactive oxygen species (ROS), especially superoxide anions. 
After the first type I photochemical reaction, several secondary reactions can occur and 
result in a diversity of oxidants, as has been thoroughly reviewed (Plaetzer et al., 2009).  
Type II photochemical reaction is when the PS de-excites from T1 to ground 
state by energy transfer, not by transfer of electrons/protons. The energy transfer has to 
be to a molecule in triplet state. Naturally occurring molecules in triplet state is rare, but 
molecular oxygen is in triplet state in its ground state, 3O2.  So, during type II 
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photochemical reaction singlet oxygen, 1O2, is formed which is highly reactive. 
Both type I and type II reactions happen in parallel and are competing reactions. 
The ratio between the two reactions depends mostly on the type of PS in use and on the 
concentration of molecular oxygen (Foote, 1991; Ochsner, 1997; Plaetzer et al., 2009). 
For most PSs used in PDT, type II reactions is the dominant reaction (Plaetzer et al., 
2009; Weishaupt et al., 1976).  
 
1.1.1.3 Molecular and cellular mechanism involved in PDT 
 
As described in 1.1.1.2, PDT generates oxidants and especially singlet oxygen. High 
amounts of oxidants can overload the anti-oxidative defence system of the cell/organism 
and create oxidative stress. Oxidative stress will induce several stress responses in the 
affected cells. Depending on the type of cellular damage and amount of damage, the cell 
could experience different types of effects including survival, autophagy, apoptosis and 
necrosis. Cell death and oxidative stress are the main effects in cells after PDT and will 
be described in section 1.2 and 1.3, respectively. 
 
1.1.1.4 PDT in the clinical use 
 
PDT on patients is more complex than PDT on cell cultures. In addition to directly 
target cell damage, eradication of tumour in patients will be supported by vascular 
damage and immune responses. The significance of the three effects is still under 
discussion and will not be treated comprehensively in this subsection. Direct tumour 
cytotoxicity is briefly described in the previous subsections, and will be described in 
more detail in section 1.2. An overview of direct cell damage and the two indirect 
mechanisms causing tumour damage (immune response and vascular damage) are 
sketched in Figure 2 and a brief description of both indirect damage pathways follows. 
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Figure 2:  Mechanisms of tumour eradication in clinical PDT. First PDT generates oxidative 
damage that can kill cancer cells directly. The induction of apoptosis and/or necrosis stimulates 
release of both inflammatory mediators and tumour associated antigens. This results first in a 
non-specific immune response followed by slowly developing adaptive immunity. In addition, 
PDT induces destruction of tumour vascularity which can contribute to tumour eradication 
through lack of oxygen and nutrients. Figure is adapted from (Pizova et al., 2012). 
 
Enhanced anti-tumour immunity after PDT:  
PDT induces oxidative stress which further triggers a variety of signal pathways, 
including signalling via Toll-like receptors. Toll-like receptors are central in innate 
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immune responses. Other central molecules for initiation of immune response are the 
expression of heat shock proteins, transcription factors such as nuclear factor țB (NF-
țB) and activator protein 1 (AP-1) which  are all reported to have increased activity 
after PDT (Castano et al., 2006; Garg et al., 2011; Garg et al., 2010; Mroz et al., 2010; 
Pizova et al., 2012; Sanovic et al., 2009; Verwanger et al., 2002).  
In addition, PDT-induced degradation of membrane lipids and generation of 
arachidonic acid metabolites, which together with histamine and serotonin released 
from damaged vasculature (activated mast and enterochromaffin cells) will lead to 
invasion and infiltration of leukocytes in the tumour (Pizova et al., 2012). After 
activation, leukocytes will take part in tumour destruction and activate the complement 
system. The complement system is a major effector system of innate immunity and 
plays a role even in adaptive immunity. Activation of the complement system after PDT 
seems to play an important role in PDT-induced immune responses (Garg et al., 2010; 
Pizova et al., 2012).  
Subsequent to activation of innate immune responses comes development of 
adaptive immunity. Necrotic cells release inflammatory cytokines (Festjens et al., 
2006).When the dying tumour cells release their antigens in the inflamed area, the 
antigens will be taken up by antigen-presenting cells. This promotes initiation of 
specific antitumor immunity. PDTs ability to induce antitumor responses is a 
mechanism pursued by scientists aiming to generate anticancer vaccines in several 
studies (Castano et al., 2006; Garg et al., 2010; Pizova et al., 2012). 
The opposite of enhanced anti-tumour immunity, immunosuppression, has been 
demonstrated (Mroz & Hamblin, 2011; Pizova et al., 2012) and appears to be correlated 
with increased treated area (Pizova et al., 2012). Frost and co-workers demonstrated that 
a decrease of light intensity prevented PDT-induced immunosuppression (Frost et al., 
2011). This may indicate that when PDT overwhelms the patients stress response 
system, immunosuppression instead of enhanced immunity will be triggered. A way of 
improving the PDT effect might be by combining PDT with immunotherapy 
(Kwitniewski et al., 2008; Pizova et al., 2012).  
PDT and tumour vascularity: 
Unlike normal tissue, tumour tissue needs to continually generate new blood vessels to 
supply the growing tumour tissue. Abnormal vascularity is one of the hallmarks of 
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tumour tissue. PDT can in some cases be used to target the tumour angiogenesis and the 
tumour blood vessels and this will contribute significantly to the final treatment 
outcome (Chen et al., 2006; Krammer, 2001; Middelburg et al., 2014). The targeting of 
blood vessels is either through passive or active targeting approaches (Chen et al., 
2006).  
  Passive vascular targeting PDT: The time period when the applied PS is mainly 
localized in the blood vessels (usually short time after administration) gives a temporal 
therapeutic window for vascular targeting (Chen et al., 2006; Senge & Radomski, 
2013). In addition, the physicochemical properties of the PS may contribute to passive 
vascular targeting, where properties like lipophilicity and high affinity for vascular 
components, such as LDL-receptors, enhance the vascular targeting (Maziere et al., 
1990).  
  Active vascular targeting PDT: Either structural modification of the PS or a 
targeted drug delivery system can cause the PS to be retained in the neovascular system 
producing a specific vascular effect. The targeting moieties are peptides, antibodies or 
other ligands that recognize molecules that are selectively expressed on newly 
synthesized blood vessels (Bhuvaneswari et al., 2009). All molecules with higher 
expression in tumour blood vessels than normal ones may potentially be targets for 
PDT.  
Clinical use of PDT to treat cancer goes back to the late 1970’s and since then 
more than 200 clinical PDT trials have been performed (Agostinis et al., 2011). 
Currently, the main PS and pro-PS in clinical use are: hematoporphyrin derivative 
(Photofrin®), mTHPC (5,10,15,20-Tetra(3-hydroxyphenyl)chlorine, Foscan®, Fospeg® 
and Foslip®), į-aminolevulinate and its derivatives (Levulan®, Metvix®, Hexvix® and 
Cysview®), benzoporphyrin derivative monoacid ring A (Verteporfin® and Visudyne®) 
and mono-L-aspartyl chlorine e6 (NPe6, Talaporfin®, Laserphyrin®) (Senge & 
Radomski, 2013). The different cancer types that are treated with PDT include; skin 
cancer (pre-cancerous actinic keratosis, basal cell carcinoma, Bowens disease), head 
and neck tumours, digestive system tumours, urinary system tumours, intraperitoneal 
malignancies, non-small cell lung cancer, mesothelioma and brain tumours (Adigbli & 
MacRobert, 2012; Agostinis et al., 2011; Baldea & Filip, 2012; Bissonnette, 2011; 
Bozzini et al., 2012; Calin et al., 2011; Ikeda et al., 2011; Karrer et al., 2013; Kharkwal 
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et al., 2011; Krammer & Plaetzer, 2008; Lee & Baron, 2011; Oosterlinck et al., 2004; 
Zhao & He, 2010). Cure rates may exceed 90%, but PDT may also be used as palliative 
treatment. PDT has nice cosmetic results compared to invasive treatment and the 
preservation of tissue function after PDT is good. Since none of the approved PSs are 
localized in the nucleus, the genotoxicity is minimal. It is therefore safe to repeat the 
PDT treatments and for PSs with rapid clearance from the body, the treatment can easily 
be repeated after a week. In addition to being a cancer treatment, PDT is also used in the 
cosmetic industry for skin rejuvenation (Karrer et al., 2013; Nootheti & Goldman, 2007) 
and as medical treatment against acne (Bissonnette, 2011; Choi et al., 2010; Kjeldstad & 
Johnsson, 1986; Lee et al., 2007; Taub, 2004). 
 
Table 1: Overview over photosensitizers that have been applied in patients, and where they are 
approved or in trials. The table was  updated in 2011 and is adapted from (Agostinis et al., 
2011). 
 
Even though much time has passed  since PDT was first reported (early 1900’s) it has 
not been included in mainstream clinical treatments (Agostinis et al., 2011). PDT is 
often used as alternative treatment, palliative treatment or in combination with other 
treatments. There is also a difference between countries in the use of PDT. The reasons 
for this delay are complicated. Hopefully a better understanding of dosimetry, utilization 
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of LED technology, a better improved PSs (with rapid clearance from the body, high 
specificity and absorption in red/far red range), and more clinical trials will improve 
PDTs potential as treatment modality. 
 
1.1.1.5 The ideal photosensitizer 
 
There are some features making one PS better than others, as outlined (Plaetzer et al., 
2008): “The ideal photosensitizer is characterized by (1) high light absorption within the 
optimal window for PDT (approximately 650 nm to 850 nm), (2) a high quantum yield 
for the triplet state, (3) a rather high photo-stability, (4) amphiphilicity, (5) high 
selectivity for the target tissue, (6) a low tendency to form aggregates, (7) no dark 
toxicity and mutagenicity, (8) no side-effects, and rapid clearing from the body after 
PDT, and, (9) a safe and reproducible PDT protocol.” (end of citation). Unfortunately, 
the ideal PS does not exist. In the studies in the present thesis the PS protoporphyrin IX 
(PpIX) has been used. PpIX fulfils many of the features describing the ideal PS, as 
elaborated upon in the subsequent sub-section. 
 
1.1.2 ALA-based PDT 
 
One of the differences between ALA-based PDT and other PDTs are that in ALA-based 
PDT a precursor of the PS is added rather than the PS itself. In ALA-based PDT either 
ALA or an ester derivative of ALA is added. Exogenously added ALA (derivative) will 
enter the heme synthesis and endogenous protoporphyrin IX will be produced (Kennedy 
& Pottier, 1992). PpIX is the active PS in ALA-based PDT. Among all tested ALA 
derivatives, three are approved for clinical PDT: 1) ALA (Levulan®), 2) methyl ALA 
(MAL, Metvix®) and 3) hexyl ALA (HAL, Hexvix® and Cysview®). The largest 
functional difference between these compounds is their lipophilicity and consequently 
the uptake mechanism of the pro-drug into the cells. In the studies in this thesis, HAL 
has been used and HAL-PDT will be described in the next sub-section.  
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1.1.2.1 Heme biosynthesis 
 
Heme is an essential molecule in most organisms and is an integral part of 
hemoproteins. Hemoproteins have diverse biological roles such as oxygen transport, 
catalysis and electron transfer/transport. The biosynthesis of heme is well studied and 
knowledge of this synthesis is essential in ALA-based PDT (Hamza & Dailey, 2012; 
Heinemann et al., 2008; Herman et al., 1998; Krammer & Uberriegler, 1996; Layer et 
al., 2010; Webber et al., 1997b).  A defect in any of the eight enzymes in the conserved 
heme biosynthesis pathway, except the two first ones will lead to a metabolic type of 
disorder named porphyria (Besur et al., 2014). In ALA-based PDT the first and rate 
limiting step in the heme synthesis is bypassed by adding exogenous ALA. 
 
Figure 3: The heme synthesis in mitochondria. For details, see text below. Enzymes in the 
pathway are highlighted in yellow and the products in black boxes. Adapted from (Ying-Ying 
Huang, 2009). 
 
Normally, ALA is formed enzymatically by ALA synthase (ALA-S) from glycine and 
succinyl coenzyme A inside mitochondria, see figure 3. ALAs activity is regulated by 
negative feedback from heme and is the initial and rate limiting, committed step in 
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heme biosynthesis. The produced ALA is then exported out of the mitochondrial matrix 
and two ALA molecules are asymmetrically condensed by ALA dehydratase (ALAD) 
into porphobilinogen. Four porphobilinogen molecules are deaminated and polymerized 
by porphobilinogen deaminase (PBGD) into hydroxymethylbilane, a linear tetrapyrrole. 
The linear tetrapyrrole is converted into uroporphyrinogen III, a cyclic tetrapyrrole, by 
uroporphyrinogen III synthase (UROS). The last cytoplasmic enzyme in this pathway is 
uroporphyrinogen decarboxylase (UROD) which decarboxylates uroporphyrinogen III 
into coproporphyrinogen III. Coproporphyrinogen III is translocated into the 
mitochondrial matrix by adenine nucleotide transporter (ANT) and ATP binding cassette 
transporter B6 (ABCB6) (Azuma et al., 2008; Chavan et al., 2013). The next step in 
heme synthesis is catalysed by coproporphyrinogen oxidase (CPOX) which oxidatively 
decarboxylates the substrate into protoporphyrinogen IX.  The penultimate step is 
catalysed by protoporphyrinogen oxidase (PPOX), and is oxidation of 
protoporphyrinogen into protoporphyrin IX (PpIX). The terminal step is the insertion of 
ferrous iron into PpIX to produce heme, catalysed by ferrochelatase (FECH).  
 
PpIX accumulation and selectivity: 
In ALA-based PDT there is a difference in PpIX accumulation in tumour tissue and 
normal tissue. PpIX is a hydrophobic photosensitizer and the goal in ALA-based PDT is 
to get a high accumulation of PpIX in target cells and a high target:normal ratio (up to 
90:1 is reported) (Abels et al., 1994). Most likely the selective accumulation of ALA-
induced PpIX in tumours cannot be explained by a single factor, but rather by a 
complex interaction of several factors. The factors contributing to accumulation and 
their interaction may further vary with location in organism, disease type, degree of 
differentiation, stage and grade of the disease and of course by the route of 
administration [reviewed in (Michael R. Hamblin, 2008)]. 
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Table 2:  Potential factors affecting selective PpIX accumulation in tumours, adapted 
from (Michael R. Hamblin, 2008). 
Global factor Specific factor 
Altered metabolic turnover in heme  Enhanced activity of pre-PpIX enzymes 
synthesis Decreased activity of post –PpIX enzymes 
 Benzodiazepine receptor expression 
Altered cellular properties of neoplasms 5-ALA uptake 
 Proliferation 
 Differentiation 
 Mitochondrial content 
 Cell density 
 Iron pool/transferrin receptor 
Environmental receptor pH 
 Temperature 
 Lymphatic drainage 
 Tissue pressure 
 Vascularization 
 Tissue integrity 
 
 
Central points in the heme synthesis for ALA-based PDT: 
The most important part is to bypass the negative feedback on ALA synthase. By adding 
exogenous ALA or ALA derivative this problem is bypassed. There are a few studies 
showing that an ALA ester enters the heme synthesis as ALA after an esterase has 
cleaved off the ester-tail (Di Venosa et al., 2006; Perotti et al., 2004). 
For selectivity of cancer cells: There is increased PBG-S and -D and reduced 
ferrochelatase activity in tumour cells compared to normal cells (Michael R. Hamblin, 
2008). The PBR receptor (benzodiazepine) is important for transport of 
coproporphyrinogen from cytoplasm to mitochondria and PBR is abundant in neoplastic 
cells (Mesenholler & Matthews, 2000; Michael R. Hamblin, 2008). 
 
Catabolism of porphyrins: 
One of the major advantages with ALA-based PDT compared to PDT with other PSs is 
the relatively rapid elimination of porphyrins and thereby short period of enhanced light 
sensitivity for patients. All redundant porphyrins are cleared from the patient in 24-48 
hours (Kennedy & Pottier, 1992; Webber et al., 1997a). Red blood cells have a lifetime 
of only 120 days. This results in excessive heme that the organism must remove. Since 
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PpIX is the last intermediate in heme biosynthesis, only lacking ferrous iron, it makes 
sense that we have a system for its degradation and removal. The liver is central in 
metabolism of heme and porphyrins, both for synthesis and degradation (Bloomer, 
1998). In the liver, heme is catabolized to bilirubin through sequential action of heme 
oxygenase and biliverdin reductase and subsequently excreted in the bile. The excretory 
pathways of the different porphyrins are determined primarily by their hydrophilicity. 
Protoporphyrin IX, which is hydrophobic, is excreted almost entirely in the bile. 
 
Properties of Protoporphyrin IX: 
Protoporphyrin IX is a tetrapyrrole which is biochemically used as a carrier molecule 
for divalent cations, such as Fe2+, Mg2+ and Zn2+.  This protein is ambiphilic, as shown 
in Figure 4, and has therefore a high affinity for membranes. The porphyrin core is 
hydrophobic and the propionate side chains constitute the hydrophilic part of PpIX. 
PpIX tends to form supramolecular assemblies such as bilayer structures and vesicles. 
When PpIX is located in aqueous solution it easily aggregates and the nature of the 
aggregation is pH-dependent (Kessel et al., 2001; Scolaro et al., 2002). In addition, it 
has been shown that PpIX has a high affinity for parts of the mitochondrial permeability 
transition pore (MPTP) (Agostinis et al., 2004; Kessel et al., 2001; Oleinick et al., 
2002).  
 
 
 
 
 
Figure 4 : The chemical structure of protoporphyrin IX. 
Molecular mass: 562.658 g/mol.  
Molecular formula: C34H34N4O4 .   
Picture adapted from 
http://commons.wikimedia.org/wiki/File:Protoporphyrin
_IX.svg. 
 
PpIX is an endogenous photosensitizer and has a typical porphyrin absorption 
spectra with a high absorption capacity around 400 nm and four Q-bands in the range 
500-650 nm, as shown in Figure 5. When excited, PpIX emits fluorescence mainly 
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around 635 nm and has an additional small fluorescence peak around 705 nm. The exact 
wavelength for PpIX spectrum depends on e.g solvent and pH (Scolaro et al., 2002). 
The typical lifetime of triplet state PS is up to seconds (Plaetzer et al., 2008)). PpIX has 
a singlet oxygen yield about 56 % (Redmond & Gamlin, 1999). 
The process when PpIX is changed into a non-fluorescent form is known as 
photobleaching or photodegradation. PpIX can be photodegraded through oxygen 
dependent mechanisms as described by Cox and co-workers in 1982 (Cox et al., 1982; 
Cox & Whitten, 1982). When PpIX is excited (subsection 1.1.1.2) the oxidants 
produced in the photochemical reactions can oxidize ground-state PpIX. Oxidation of 
PpIX can result in photoproducts which absorb and emit light at slightly longer 
wavelengths (Cox & Whitten, 1982; Ericson et al., 2003; Krieg & Whitten, 1984; Moan 
et al., 1997). 
 
 
Figure 5: A characteristic absorption and fluorescence spectrum for protoporphyrin IX. 
Absorption spectrum is presented in black line, left axis and fluorescence in red line, right axis. 
The figure is adapted from (Valentine et al., 2013). 
 
1.1.2.2 HAL-PDT 
 
In the studies in this thesis an esterified derivate of ALA with a tail length of six carbons 
has been used. The derivative is named hexylaminolevulinate (HAL) and is shown in 
figure 6. Hexylaminolevulinate has been launched under the trade names Hexvix and 
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Cysview (PhotoCure, Oslo, Norway) and is approved for photodiagnosis (PDD) of 
bladder cancer in all EU/EAA countries and the US, respectively. HAL-PDD was 
recommended for bladder cancer detection in the guidelines of the European 
Association of Urologists in 2004 and 2005 (Oosterlinck et al., 2004; van der Meijden et 
al., 2005).    
 
Figure 6: Chemical structure of hexylaminolevulinate. 
Chemical formula: C11H21NO3.  
Molecular weight: 215.29.  
Picture is adapted from 
http://www.medkoo.com/Anticancer- 
approved/Structures/img-hexaminolevulinate.gif 
The characteristics, application and perspectives for the use of ALA derivatives have 
been thoroughly reviewed (Fotinos et al., 2006). How ester derivatives of 5-ALA enter 
the heme synthesis is still not fully solved. Whether ALA esters enter the heme 
synthesis as 5-ALA after esterases have cleaved off the ester tails, enter directly or after 
other degradation reactions is still debated (Tunstall et al., 2002), but there are results 
supporting esterases to have a crucial role (Di Venosa et al., 2006; Perotti et al., 2004). 
HAL has been shown to be superior to ALA both regarding porphyrin formation and 
drug penetration (Kiesslich et al., 2014; Lange et al., 1999; Marti et al., 2003). 
 
1.1.3 Light  
 
Light is electromagnetic waves and light/photon energy is given by  
 
E = h f = h c / Ȝ 
E (energy) h (Planck’s constant) and c (speed of light is constant, c= f Ȝf (frequency) Ȝ(wavelength). 
 
From this equation, we see that the energy decreases with increasing wavelength. 
Electromagnetic radiation is energy which can be emitted and absorbed by charged 
particles. It has a wavelike behaviour and consists of both an electric and magnetic field.  
The electromagnetic spectrum ranges from gamma rays Ȝa-13 m) to radio waves Ȝ
~ 103 m). Visible light is only a small part of the spectrum ranging between UV-light 
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and infrared radiation and ranges from 400 nm to 800 nm. 
 
Figure 7: Electromagnetic spectrum, including visible light and its colours and corresponding 
wavelengths. Figure is adapted from (2015-01-28): http://www.ces.fau.edu/nasa/module-
2/radiation-sun.php 
 
Most PSs used in PDT absorbs light in the red range (600-700nm). The first law of 
photochemistry says that light must be absorbed by a compound before a photochemical 
reaction can take place. Since absorption defines the critical step for photochemical 
reaction and the amount of incoming photons determines the likelihood of absorption, a 
simplified description of light dose is the two factors: light intensity and illumination 
time.  
 
Light dose (J/cm2) = light intensity (W/cm2) * time (sec), 1 Ws = 1 J. 
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Figure 8: Light propagation through tissue and the penetration capacity of the different light 
colours. Figure is adapted from (Agostinis et al., 2011). 
 
Light in tissue: 
When applying light for PDT on patients one has to consider the interactions between 
light and tissue. The same processes applies also for PDT on cell lines, but makes less 
impact since the light usually is applied from below the cell dish/plate/flask. There are 
four main processes for light targeting tissue; refraction, reflection, scattering and 
absorption, as shown in Figure 8 and Figure 9.  
Snell’s law describes refraction of light in the interface between two media with 
different refractive indices and Fresnel’s law describes reflection in the same interface. 
Both processes are determined by their relative values of refractive indices and are 
proportional to the incidence angle. Both processes can be minimized by applying the 
light beam perpendicular to the interface. The most pronounced effect on light intensity 
and direction comes from scattering of light. Scattering is a complex process which 
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widens the light beam and thereby reduces the light intensity in addition to changing the 
light beam direction (and wavelength, depending on the particle size). The last process 
is absorption. Absorption causes light intensity to reduce with increasing penetration 
depth and is described by Lambert-Beer’s law, which has an exponential form. 
 
 
Figure 9: The different interaction mechanisms between tissue and light with the corresponding 
physical laws. Figure is adapted from (Plaetzer et al., 2009).  
 
Tissue consists of several molecules/chromophores, which absorb incoming light. The 
most important ones are water, oxyhemoglobin (HbO2) and deoxyhemoglobin, melanin 
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and cytochromes. The combined absorption spectrum of these chromophores defines the 
optical window for PDT in tissue as seen in Figure 10 (Plaetzer et al., 2009). The optical 
window (600-1400nm) from these absorption spectra is further reduced since light 
above 850 nm does not contain enough energy to excite a PS into triplet state with high 
enough energy to produce singlet oxygen. The lowest energy difference between ground 
state 3O2 and 1O2 is 0.98 eV which corresponds to a wavelength of 1270 nm, the natural 
phosphorescence of 1O2. The triplet state PS has to exceed this energy and due to 
thermal losses in the photophysical process, the upper wavelength limit for PDT to 
efficiently produce 1O2 is 850 nm (Juzeniene et al., 2006; Plaetzer et al., 2009). 
 
 
Figure 10: The ‘optical window’ for PDT. The absorbance spectrums for some tissue 
components are presented. Absorption of light by tissue components limits the wavelength range 
suitable for PDT to about 650–1400 nm. This range is further reduced, since PS triplet-state 
molecules excited by Ȝ! nm have too low energy to produce singlet oxygen efficiently.  
Figure is adapted from (Plaetzer et al., 2009). 
 
The penetration depth of light into tissue also depends on the wavelength of the 
incoming light, as presented in Figure 8. Penetration depth is defined as 1/e of the 
incoming light, and from Beer-Lamberts law in Figure 9, we see that penetration depth 
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increases with increasing wavelength. This is measured in different tissue for different 
wavelengths. Blue light penetrates about 1-2 mm into tissue and red light about 5-6 mm 
(Juzenas et al., 2009; Juzeniene et al., 2006). 
 
1.1.3.1 Light sources for PDT, particularly LED 
 
Different types of lamps have been used and are used for PDT (Brancaleon & Moseley, 
2002). There are different types of broad band lamps, more narrow wavelength range 
and monochromatic. Broad band lamps have the advantages that they are cheap and 
easy to use, have high light intensity and can illuminate large areas. However, they 
produce heat, have broad spectra and cannot easily be used for optical fibres. Lasers 
have the advantages of monochromatic light, limited heat production, are easily used 
with optical fibres, can deliver high light intensity both as pulses and continuously. 
However, most lasers are expensive and are not so straight forward to handle. The third 
and perhaps best suited light source option is LED (light emitting diode). LEDs have 
narrow bandwidth, are cheap, can be used for fibre optics, produce minimal heat, and 
can illuminate large areas. Perhaps the largest disadvantage is the upper limitation in 
light intensity from LEDs. Since LED based arrays are the main light source in this 
thesis a brief introduction of LEDs is required.  
A light emitting diode is a semiconductor light source which converts electrical 
energy into light energy. When voltage is applied, electrons can recombine with electron 
holes within the semiconductor and this recombination releases energy in form of 
photons. This effect is termed electroluminescence and the colour of the emitted light is 
defined by the energy gap in the semiconductor (defined of the material forming the p-n 
junction). A problem is that LED efficacy drops with increasing current applied, known 
as droop; this limits the output light intensity and results in heating when higher current 
is applied. The cause of the droop is still debated, but many points to the Auger 
recombination. In simple words: instead of emitting a photon when an electron 
recombines with a hole, a second electron (Auger electron) is ejected out of the atom. 
LED performance is temperature-dependent and conventional LEDs are made from a 
variety of inorganic semiconductor materials. Most materials used in LEDs have high 
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refractive indices and this restricts the output direction from a LED. Most LEDs emit 
light straight forward in a cone shape with cone walls around 15°.  
A new form of illumination source for PDT is the flexible organic LEDs 
(OLED). The organic LEDs have a broader wavelength range, are flexible and emit 
diffuse light. These features make it possible to develop light emitting patches/bandage 
where the patient easily can carry the power source in his/her pocket (Attili et al., 2009).  
 
1.1.4 Summary of PDT 
 
PDT is a two-step process where the factors are non-toxic separately, but when 
combined they become cytotoxic. The PS localizes quite specifically to cancer cells 
(high tumour:normal ratio) and is activated by visible light. Activated PS generates 
oxidants through oxygen dependent photochemical processes. An oxidant level beyond 
the cells anti-oxidative defence capacity may result in oxidative stress, oxidative 
damage and cell death. Cell death will be described in section 1.2 and oxidative stress in 
section 1.3. It is important to keep in mind that there is a difference between PDT on 
patients and on cell cultures, especially regarding the complexity of the target and 
thereby the responses. Light is perhaps the easiest factor to adjust in PDT and the 
applied light dose is given by the light intensity multiplied by the illumination time. One 
of the most utilized PDT types is ALA-based PDT. Exogenously added ALA (or 
derivative, such as HAL) enters the heme synthesis and endogenous PpIX accumulates 
in target cells. PpIX is activated both by blue and red light, clears rapidly from the 
organism and has a high cancer: normal ratio. HAL-PDT show superior properties (e.g. 
PpIX production and tissue penetration) compared to ALA-PDT and have been used in 
this thesis. 
 
1.2 Cell death 
 
At the start of this thesis introduction it was stated that PDT may eradicate cancer 
through interfering with angiogenesis, immune responses and direct cell kill. In this 
subsection the direct cell kill in form of the different cell death pathways will be 
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addressed. The studies included in this thesis comprise only in vitro level research and 
consequently direct cell kill is a main focus in the thesis. This subsection will give an 
introduction to the cell death pathways apoptosis, autophagy and necrosis.  To 
understand these pathways is important both for knowing the cause of several diseases 
and for development of possible therapeutic strategies, including improvement of PDT. 
Cell death induced by PDT has been  studied in quite a few laboratories (Castano et al., 
2005; Kushibiki et al., 2013; Mroz et al., 2011; Plaetzer et al., 2002; Yoo & Ha, 2012), 
but since PDT is a diversified treatment and cancer a diverse disease, a detailed 
understanding of mechanisms is far from complete. First, necrosis will be addressed, 
subsequently autophagy, last and in more detail apoptosis will be addressed. Throughout 
this subsection the role of PDT (and especially HAL-PDT) will be included. The 
morphological properties of each pathway are illustrated in Figure 11. 
 
Figure 11:  This figure illustrates the morphological properties of each cell death pathway. 
Modified from (Henriquez et al., 2008).  
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1.2.1 Necrosis 
 
Necrosis is a cell death pathway with some distinct morphological properties as 
depicted in Figure 11. Whether necrosis is the main cell death pathway induced by PDT 
depends on several factors, such as type of sensitizer used, applied light dose and cell 
line examined. This is not fully understood yet and will not be discussed further in this 
subsection. Anyhow, necrosis is an important cell death pathway in PDT and will be 
briefly discussed. 
  Necrosis is mostly caused by external factors such as toxins, severe injuries and 
infections and has frequently a damaging effect on the surrounding tissues as well. 
Briefly; extensive stress to the cell may cause necrosis, while less stress causes 
apoptosis or repair. Necrosis also has a more damaging outcome for the surrounding 
cells than the more controlled apoptosis. Necrosis is often referred to as an accidental 
death mode (Henriquez et al., 2008; Kroemer et al., 2007).  In recent reviews [(Vanden 
Berghe et al., 2014) and references therein] the perception of necrosis has changed to an 
active choice probability and controllable cell death mode.  Perhaps it is necessary to 
distinguish between accidental and programmed necrosis.  Accidental necrosis normally 
occurs within 2-4 hours after the triggering injury (Kroemer et al., 2007), such as 
illumination during PDT.  Necrotic cells have the property to induce local inflammation 
(Kroemer et al., 2007). This happens mainly because necrotic cell eventually burst and 
intracellular substances come in physical contact with neighbouring cells. Since 
inhibition of other cell death pathways can lead to necrosis, it is by some suggested as a 
back-up pathway (Henriquez et al., 2008).  
The extent of the injury mainly determines the final phenotypic appearance of 
the cell. Main features of necrosis are listed in Figure 11; swelling of organelles and the 
cell, loss of membrane integrity and no DNA laddering.  Necrosis has few known 
specific biochemical markers (Baumann, 2012). Membrane impermeable markers 
tagged for an intracellular target are often used to detect necrosis and electron 
microscopy can be used for identifying necrotic cells.   
Different mechanisms can lead to necrotic cell death, including high doses of 
ROS (Henriquez et al., 2008). This overview will only highlight some of the ROS-
mediated mechanisms, since PDT generates ROS through photochemical reactions. 
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Excess of ROS can rapidly damage cells by oxidizing essential components, such as 
lipids, proteins and DNA, thus disturbing vital cell functions (Henriquez et al., 2008; 
Kroemer et al., 2007).  ROS also function as signal molecules in pathways leading to 
both apoptosis and necrosis (Henriquez et al., 2008). Several studies indicate that low 
formation of ROS induces apoptosis, while high formation of ROS induces necrosis, 
[reviewed in (Henriquez et al., 2008; Schieber & Chandel, 2014)], e.g. low and high 
doses of PDT.  Another way by which ROS can induce necrosis is by inhibiting 
apoptosis through suppressing caspase activation [(Henriquez et al., 2008) and 
references therein]. This is possible since catalytic activity of caspases is receptive to 
redox regulation. 
Thus far, few biochemical hallmarks of necrosis have been established 
(Baumann, 2012) and it is only recently that the view of necrosis as an accidental death 
mode is changing into a possibly programmed death mode (Vanden Berghe et al., 2014). 
Necrosis is a total cell collapse with some distinct morphological changes, caused by 
severe stress, such as high dose PDT, and it evokes inflammation. 
 
1.2.2 Autophagy 
 
PDT induces oxidative stress and autophagy is well known to be induced by ROS (Garg 
et al., 2013; Kessel & Reiners, 2007; Kessel et al., 2006; Reiners et al., 2010). 
Autophagy is a catabolic process involving degradation of intracellular components by 
lysosomal mechanisms, which become up-regulated under stress conditions. The 
autophagy process is regulated and plays an important role in cell maintenance, growth, 
development and future destiny (Navarro-Yepes et al., 2014). The best known function 
of autophagy is degradation and recycling of nutrients from not so important cellular 
components to more important components of the cell during cell starvation. But it also 
has a very important role in clearance of ROS damaged organelles and irreversibly 
oxidized proteins. The understanding of autophagy has improved considerably in the 
last decade (Ravikumar et al., 2009). Even though autophagy is mainly looked upon as a 
cell survival mechanism, some evidence points towards that it has a role in cell death 
(Fulda & Kogel, 2015; Tsujimoto & Shimizu, 2005b). 
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There exist different types of autophagy, including chaperon-mediated 
autophagy, microautophagy and macroautophagy (Ravikumar et al., 2009). 
Macroautophagy is the process where cells form double membrane vesicles called 
autophagosomes and is the type of autophagy which will be emphasized in this thesis 
and further on referred to as autophagy. 
 
1.2.2.1  Mechanisms of autophagy: 
 
Autophagy starts by a flat membrane cistern wrapping around cytoplasmic organelles 
and/or a part of the cytosol. This forms a closed double membrane bound vacuole called 
autophagosome. These maturate stepwise by fusing with endosomal and/or lysosomal 
vesicles, generating amphisomes or autolysosomes, respectively (Tsujimoto & Shimizu, 
2005a). Autolysosomes finally digest the sequestered cellular components by lysosomal 
hydrolases (Kroemer et al., 2007; Tsujimoto & Shimizu, 2005a). For a more detailed 
description of the autophagosome formation, the reader is referred to (Ravikumar et al., 
2009).  
Autophagy is regulated by PI3 kinase type I and III (Tsujimoto & Shimizu, 
2005a). PI3 kinase Type I is activated by growth factors, such as insulin. The type I 
pathway is inhibited through PDK1 and Akt, which regulate mammalian target of 
rapamycin (mTOR). PI3 kinase type III promotes the nucleation of autophagic vesicles.  
mTOR is regulated by many proteins, so it is likely that the autophagy process is very 
complex. Additionally was an mTOR independent autophagic pathway found in 2005 
(Sarkar et al., 2005).  
 
1.2.2.2 Autophagic cell death 
 
The role of autophagy in cell death remains incompletely explored. The functional 
relationship between necrosis/apoptosis and autophagy is complex and may either 
contribute to cell death or be a part of the cellular defence against acute stress (Booth et 
al., 2014; Marino et al., 2014; Nikoletopoulou et al., 2013).  An overview of the role of 
autophagy in cell death will be given in the following text. 
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Autophagic cell death is morphologically defined as a type of cell death occurring in the 
absence of chromatin condensation and presence of massive autophagic vacuolization of 
the cytoplasm, see Figure 11. But according to (Kroemer et al., 2009) and (Tsujimoto & 
Shimizu, 2005a) the term “autophagic cell death” simply describes cell death with 
autophagy. An increased number of autophagosomes are sometimes seen in dying cells, 
but this is often not the result of autophagy-mediated cell death (Ravikumar et al., 
2009). The functional interaction between apoptosis and autophagy is indicated by the 
following observation: Enhancing autophagy gives an anti-apoptotic effect, whereas 
blocking of autophagy increases cells sensitivity to pro-apoptotic insults. 
Knowledge on the molecular basis of autophagic cell death has advanced 
tremendously in recent years, but remains incompletely understood (Birgisdottir et al., 
2013; Fulda & Kogel, 2015; Zhang, 2015). Autophagic cell death is dependent on 
autophagy proteins involved in the formation of autophagosomes (Shimizu et al., 2004; 
Yu et al., 2004). The details of the autophagosome formation and the different ways to 
cell death are well reviewed by Fulda and Kögel (Fulda & Kogel, 2015). The perhaps 
three most central players for this process are the autophagic molecules Beclin-1 (also 
called Atg6), Atg5 and Atg7. Their binding to other molecules are required for 
activation of different stages of the pathway.  One research group has shown that 
autophagic death of mouse cells, L929, is dependent on Jun N-terminal kinase (Jnk) (Yu 
et al., 2004). How Jnk and autophagy is linked was not determined, but the importance 
of Jnk to autophagic cell death was confirmed by unpublished results in Bax/Bak 
deficient mouse embryonic cells (Tsujimoto & Shimizu, 2005a). Also, Bak/Bax 
deficient mouse embryo cells require anti-apoptotic protein basal-cell lymphoma-extra 
large (Bcl-xL) or Bcl-2 to perform autophagic cell death (Tsujimoto & Shimizu, 2005a).  
It is also shown that starvation induces Jnk1 activity which phosphorylates Bcl-2, 
thereby disrupting the interaction between Beclin-1 and Bcl-2 and inducing autophagy 
(Wei et al., 2008). 
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1.2.3 Apoptosis 
 
Apoptosis has been  extensively studied and many well written reviews are available 
(e.g.(Cohen, 1997; Elmore, 2007; Green & Reed, 1998; Hengartner, 2000; Nagata, 
1997; Porter & Janicke, 1999; Thompson, 1995; Zimmermann & Green, 2001)). The 
role of apoptosis in PDT has also been well reviewed (e.g. (Agostinis et al., 2004; 
Kessel & Luo, 1998; Kessel & Reiners, 2007; Kessel et al., 2006; Kiesslich et al., 2013; 
Oleinick et al., 2002; Plaetzer et al., 2005)) 
Programmed cell death was first described by Lokshin and Williams in 1965 
(Lockshin & Williams, 1965) and apoptosis was morphologically identified by Kerr et 
al in 1972 (Danial & Korsmeyer, 2004; Galluzzi et al., 2014; Kerr et al., 1972). 
Apoptosis is a mode of cell death executed by an intracellular program and has distinct 
morphological features (Danial & Korsmeyer, 2004; Galluzzi et al., 2014). During 
apoptosis the cell shrinks and condenses, the cytoskeleton collapses, the nuclear 
envelope disassembles, the nuclear chromatin condenses and breaks up into fragments, 
the cell surface blebs into apoptotic bodies and the cell surface becomes chemically 
altered in such a way that it can be recognized by neighbouring cells/macrophages and 
phagocytosed. See Figure 11 and Figure 12 for morphological hallmarks and picture. 
Apoptotic cells in vivo are rapidly phagocytosed, thus few apoptotic cells are seen in 
tissue and it has minimal effect on the neighbouring cells. If the apoptotic cells are 
phagocytosed before the late phase, they will not evoke an inflammatory response 
(Rock & Kono, 2008).  
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Figure 12: This images show apoptotic and necrotic cells. A) presents an apoptotic cell grown 
in a culture dish, B) shows an apoptotic cell in tissue that has been endocytosed by a phagocytic 
cell, C) a necrotic cell grown in culture dish. Adapted from (Alberts et al., 2008).  
 
In animal development the apoptotic process removes unwanted cells and regulates the 
cell number. In adult tissue, apoptosis plays an important role in the tight regulation of 
cell death and division. In different control processes, the outcome is often apoptosis 
when the cell damage is severe enough, thus apoptosis is a part of the cell quality 
regulation.  
Apoptosis is divided into two main pathways, the extrinsic and intrinsic 
pathway, depending on which stimuli trigger the onset of apoptosis. The extrinsic 
pathway is the process in which extracellular signals trigger apoptosis by binding to 
specific death receptors. The intrinsic pathway is when intracellular apoptotic signals 
trigger to the onset of apoptosis. The intrinsic pathway can be sub-divided into different 
pathways, depending on where the apoptotic signal cascade origins and its progress.  
 
1.2.3.1 In general 
 
Some features of the different apoptotic pathways are common and are often used as 
markers for apoptosis in research.   
Apoptosis is biochemically recognizable. Some of the common apoptotic events will be 
addressed in the subsequent text. One of the early events in the apoptotic process is the 
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flipping of a phospholipid, phosphatidylserine, from inner membrane to the outer 
membrane surface. Phosphatidylserine can be labelled by fluorescent tagged Annexin V 
and measured by different fluorescent techniques. Other cells read the exposed 
phosphatidylserine as an “eat me” signal and phosphatidylserine inhibits cytokines. 
Apoptotic cells often lose their electrical potential across the inner mitochondrial 
membrane and release cytochrome c from mitochondria into cytosol. Both of these 
events can be labelled by different techniques. Extensive release of cytochrome c clearly 
happens before swelling and rupture of mitochondria (Danial & Korsmeyer, 2004). 
During apoptosis chromosomal DNA is cleaved into fragments of distinct sizes by 
endonucleases (Kitazumi & Tsukahara, 2011). Chromosomal DNA is cleaved in the 
linker region between nucleosomes, which results in DNA fragments of distinct sizes. 
DNA fragmentation can be recognized by a characteristic gel electrophorese pattern or 
the new DNA ends can be marked by the TUNEL assay (Loo, 2011). 
The different apoptotic pathways origin from separate sites in the cell, but will 
largely assemble at the same effector caspases and result in caspase-dependent cell 
death. There are some less common caspase-independent mechanisms death modes.  
Both the caspase dependent and independent pathways have some common 
mechanisms. This crosstalk makes substitutions of one pathway with another possible. 
Despite all these complexities, apoptosis uses some main mechanisms: The caspase 
cascade coordinates the process of the characteristic changes in morphology during 
apoptosis; there are two separate main pathways for trigging this cascade, the intrinsic 
and extrinsic pathway. Below, the caspase cascade will be briefly described and 
subsequently both the intrinsic and extrinsic pathway will be described. 
 
1.2.3.2 The caspase cascade 
 
The mechanisms of the caspase cascade are well studied (Chan et al., 2000; Choi et al., 
2002; Cohen, 1997; Fuentes-Prior & Salvesen, 2004; Furre et al., 2006; Granville et al., 
1998; Janicke et al., 1998; Kurokawa & Kornbluth, 2009; Salvesen & Riedl, 2008; 
Thornberry & Lazebnik, 1998; Wang et al., 2003). Caspases are proteases that have 
cysteine at their active site and cleave their target protein at specific aspartic acid 
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residues. Caspases are synthesized as inactive pro-caspases which are typically 
activated by proteolytic cleavage. Pro-caspase cleavage is catalysed by other active 
caspases and splits the pro-caspase into a large and a small subunit. The two subunits 
assemble into a heterodimer and the assembly of two such dimers gives an active 
tetramer. 
Once activated, caspases cleave other pro-caspases in an amplifying cascade. 
This proteolytic cascade starts with an initiator pro-caspase, which cleaves an 
executioner pro-caspase (also called an effector pro-caspase), which again cleaves 
another executioner/effector pro-caspase or a target protein (Shalini et al., 2014). The 
caspase cascade is destructive, self-amplifying and irreversible. Which caspases that are 
involved, depend on cell type and stimulus, but perhaps the most central caspase is 
caspase-3, which is an effector caspase (Choi et al., 2002; Janicke et al., 1998; Porter & 
Janicke, 1999).  
Two separable pathways are well documented to activate the pro-caspases, the 
intrinsic and the extrinsic pathway. 
 
1.2.3.3 Intrinsic pathway 
 
The intrinsic pathway is usually trigged as a response to different types of stress, such as 
DNA damage, toxins, radiation, hypoxia, oxidative stress or hypoxia, or absence of  
nutrients or extracellular survival signals (Movassagh & Foo, 2008). The main feature 
of the intrinsic pathway is the permeabilization of the outer mitochondrial membrane 
and the resulting release of apoptogenic molecules into cytosol (Figure 13). Since PpIX, 
the photosensitizer in HAL-PDT, is produced in mitochondria and induced singlet 
oxygen has a short diffusion length intracellularly, mitochondria is a likely target and 
consequently the intrinsic pathway would be the likely mechanism initiated. 
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Figure 13: Extrinsic and intrinsic apoptosis. “Different pathways of caspase activation leading 
to apoptosis. The extrinsic or death receptor pathway of caspase activation is initiated by the 
binding of a member of the tumour necrosis-factor (TNF)-family of death-receptor ligands to 
their cognate receptors (in this picture FasL and Fas). Through their death domain, 
oligomerized receptors, recruit adaptor protein (FADD), which in turn recruits pro-caspase-8 
and/or pro-caspase-10 to form the death inducing signalling complex (DISC). As part of the 
DISC pro-caspase-8 becomes autocatalytically activated and in turn cleaves effector pro-
caspase-3/-7. The effector caspases then process different substrates leading to apoptotic cell 
death. A separate pathway of caspase activation involves the mitochondrion as a central 
organelle and is therefore called the mitochondrial or intrinsic pathway. Different death signals, 
including PDT, can induce the permeabilization of the outer mitochondrial membrane leading 
to the release of apoptogenic molecules, such as cytochrome c, Smac/DIABLO and 
endonuclease G from the intermembrane space of the mitochondrion. The release of these 
molecules is tightly controlled by different members of the Bcl-2 family. The release of 
cytochrome c promotes, in the presence of dATP/ATP, the formation of the apoptosome, which 
includes Apaf-1 (apoptotic protease activating factor-1) and pro-caspase-9. Autocatalytic 
activation of caspase-9 triggers the activation of effector caspases, ensuring apoptotic cell 
death. A cross-talk between those two pathways is provided by cleavage of the BH3-only protein 
Bid by activated caspase-8. Truncated Bid in turn promotes Bax oligomerization and insertion 
into outer mitochondrial membrane, leading to subsequent cytochrome c release”(citation end). 
Figure and text adapted from (Agostinis et al., 2004). 
 
Cytosolic cytochrome c binds to Apaf-1, which in presence of dATP or ATP leads to 
pro-caspase-9 activation in an oligomeric complex called the apoptosome (Alberts et al., 
2008; Movassagh & Foo, 2008). Caspase-9 activates down stream caspases, including 
pro-caspase-3, which triggers apoptosis. In parallel with cytochrome c, other 
mitochondrial intermembrane proteins are also released into cytosol, such as EndoG 
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(endonuclease G), AIF (apoptosis inducing factor) and Smac. EndoG and AIF further 
translocate to the nucleus and promote caspase-independent DNA breakdown. An 
irreversible loss of mitochondrial function (e.g. caused by PDT) could also release 
apoptotic proteins (Green & Reed, 1998; Kessel & Luo, 1998; Kroemer et al., 2007; 
Orrenius et al., 2007; Ott et al., 2007; Sinha et al., 2013). 
The release of these apoptotic proteins is thought to occur through mitochondrial 
membrane permeabilzation (MMP), which is defined as a sudden permeabilization of 
the inner mitochondrial membrane for molecules below 1500 Da. The opening of this 
MMP pore causes a change in the ion gradient and the outer mitochondrial membrane 
bursts due to osmotic swelling (Kroemer et al., 2007).  
The intrinsic apoptotic pathway is tightly regulated by the Bcl-2 family of 
proteins (B cell lymphoma 2). This family of proteins is also involved in the extrinsic 
apoptotic pathway and apoptosis triggered from Ca2+ imbalance or the unfolded protein 
response in endoplasmic reticulum. The pro-apoptotic family members (Bax, Bid, Bak 
and Bim) and the anti-apoptotic members (Bcl-2 and Bcl-XL) are found at different 
subcellular localizations and are activated either by relocalization, up regulation or post 
translational modification. 
 
1.2.3.4 Extrinsic pathway 
 
The extrinsic pathway of apoptosis is trigged when extracellular signal proteins bind to 
death receptors on the cell-surface. Death receptors are transmembrane homotrimers 
that belong to the tumour necrosis factor (TNF) receptor family (e.g. Fas, TNF-RI and 
TRAIL receptor). The ligands are also homotrimers and belong to TNF family of signal 
proteins (e.g. FasL, TNF-Į and TRAIL). The ligand to receptor binding results in 
reorganization of the inactive Fas complex and stimulates recruitment of adaptor 
protein, such as Fas-associated via death domain (FADD), which in turn activates 
procaspase 8 and/or 10. Caspase 8/10 activates the death-inducing signalling complex 
(DISC), which activates the apoptotic caspase cascade by activating the initiator 
caspase. Once the caspase cascade has been initiated, the extrinsic pathway is similar to 
the intrinsic pathway. 
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1.2.4 Summary of cell death 
 
Apoptosis, autophagy and necrosis are three different death pathways, caused by 
different stimuli and executed by different mechanisms. At the same time there exist 
links between all three pathways and functional interaction between them. All three 
pathways contribute to the pathogenesis of several diseases and represent possible 
targets for treatment. Probably all three death pathways are involved in PDT-induced 
cell death, but at varying degrees. The main goal of PDT is to kill the cancer cells and 
for this matter all three pathways may do the job. But since they will affect the adjacent 
regions differently a combined action of them could give additional effects not obtained 
by a single mechanism. Consequently, knowledge of what is activated after PDT is well 
worth studying. 
 
1.3 Oxidative stress 
 
Oxidative stress is basically when the amount of oxidants (e.g. ROS) exceeds the 
capacity of the antioxidants defence system.  As described in section 1.1.1.2 
Mechanisms of PDT; photochemical reactions PDT generates ROS through 
photochemical reactions. This is probably the main direct effect of PDT. Subsequently, 
this oxidative stress causes cell death through mechanisms triggered by oxidative stress 
and consequences thereof.  The focus of this section will be oxidative stress induced by 
PDT, oxidative stress in general, oxidation of proteins and lastly redox signalling. 
 
1.3.1 Oxidative stress induced by PDT 
 
As illustrated with the Jablonski diagram in Figure 1 the excited photosensitizer 
de-excites either by energy transfer to oxygen (type II reaction) creating singlet oxygen 
(1O2) or by transferring electrons/protons (type I reaction) to a molecule in the vicinity, 
thus generating radicals. Molecular details of the oxidants produced by PDT are 
illustrated in Figure 14 and the subsequent text. 
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The radical anion/cations formed by type I reaction are likely to further react 
with oxygen through secondary photochemical reactions, forming reactive oxygen 
species (ROS). When a PS transfers an electron directly to oxygen, superoxide anions 
are produced. The not so reactive superoxide molecules can react with each other 
resulting in the more reactive hydrogen peroxide (H2O2). Hydrogen peroxide can easily 
pass through membranes and is therefore not restricted to one cellular compartment. The 
lifetime (half-life of 1 ms) of H2O2 is also much longer than many ROS’ and combined 
with the membrane permeability it is a very potent ROS for producing cellular damage 
(Cheeseman & Slater, 1993). 
 
 
Figure 14: “Overview of photochemical reactions during PDT. Several types of primary and 
secondary photochemical reactions cause production of reactive oxygen species and dose-
dependent cellular damage. H2O2, hydrogen peroxide; 1O2 (O2(1ǻg)), singlet oxygen (excited 
state); O2 (3Ȉ-g), triplet oxygen (ground state); O2-Ɣ , superoxide anion; OH-Ɣ, hydroxyl radical; 
SOD, superoxide dismutase; X-/+, anion/cation species; XƔ, radical species.”(citation end). 
Figure and text adapted from (Plaetzer et al., 2009). 
 
From photoreaction type II, singlet oxygen is produced by energy transfer from 
the excited PS to ground state oxygen. Singlet oxygen is very reactive and can diffuse 
trough membranes, but it has a short lifetime of about 0.1 μs (Moan, 1990; Moan & 
Berg, 1991). The diffusion length is maximum 30 nm intracellularly (Plaetzer et al., 
2009). Consequently, the intracellular localization of the PS is determining the site of 
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cellular damage during PDT. Nearly all PSs used in PDT have a high quantum yield for 
1O2 IRUPDWLRQࡱ 0.3-0.5) (Juzeniene et al., 2006; Moan & Berg, 1991; Moan & Juzenas, 
2006).  
A mix of type I and type II reaction occurs during PDT and depending on the 
PDT dose, the induced oxidative stress could be quite massive. In the following sections 
a more general discussion on oxidative stress will be given. 
 
1.3.2 Oxidative stress in general 
 
During oxidative stress, cell components can be damaged, including DNA, RNA, lipids 
and proteins. The effect of oxidative stress depends on its extent. Small changes can be 
overcome by the cell, but severe oxidative stress may cause cell death (Stadtman & 
Levine, 2002). It has been shown that moderate oxidative stress causes apoptosis and 
stronger stress causes necrosis (Lennon et al., 1991), see figure 15.  Depending on the 
type of damage, oxidative stress can be harmless, pathogenic (Dalle-Donne et al., 
2006b) or may promote aging. To cover all of the aspects of oxidative stress in this 
thesis would require comprehensive efforts beyond the scope of the present review 
(Rahal et al., 2014). Consequently, further discussion is restricted to oxidative stress on 
proteins. 
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Figure 15: A simplified illustration of how increasing degree of oxidative stress/PDT-induced 
damage activates different cellular responses. The basic view is that the response is dose-
dependent with a transition from (low dose) survival (and autophagy) to apoptosis to necrosis 
(high dose). Figure adapted from (Plaetzer et al., 2005). 
 
Redox reaction - In a redox reaction both reduction and oxidation take place and 
redox refers to all chemical reactions where atoms get their oxidation state altered. 
During oxidation of the molecule, there is a loss of electrons; an increase in oxidation 
state. Likewise, during reduction there is a gain of electrons; a decrease in oxidation 
state.   
Reactive oxygen species (ROS) are oxygen-containing molecules which are 
chemically reactive. ROS are highly reactive due to unpaired electrons in the outer 
valence shell. 
A radical/free radical has either unpaired electrons or an open outer shell 
configuration. So in other words; a ROS is a free radical which contains oxygen.  
Singlet oxygen is not a free radical and is thereby not a ROS. Nevertheless, it is very 
reactive and can react with most molecules due to its quantum state. 
The most reactive radicals tend to be less selective, unlike less reactive radicals, which 
tend to be more selective.  
Often the term oxidant (oxidizing agent) is used. This is a wider concept and 
includes all molecules which remove electrons from another molecule in a redox 
reaction. By using this term, incorrect use of the terms ROS and radicals is avoided. In 
addition, the term pro-oxidant is worth noticing. Pro-oxidants are chemicals which 
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induce oxidative stress either through creating oxidants or by inhibiting antioxidant 
systems. 
Oxidative stress - A biological system will normally be in a balanced redox state 
when the antioxidant defences efficiently cope with the background level of oxidants. If 
either the antioxidant defence system decreases its capacity or the level of oxidants is 
raised, the biological system will enter a state of oxidative stress.   
Antioxidant defence system - Oxidative stress is also called the paradox of 
aerobic life. Organisms have developed strategies of antioxidant defence that handle the 
negative effects of oxidative stress, The defence strategies involved may be subdivided 
into three levels; protection, interception and repair (Sies, 1993).   
Nonenzymatic antioxidants include both lipophilic and hydrophilic compounds; 
the lipophilicity depends on the location of action. The basic process is deactivation of 
the damaging compound. For radicals this means to transform them into a non-radical 
end product. The other basic process is translocation of the damaging compound from a 
sensitive target site to a less deleterious cell compartment. 
Enzymatic antioxidants exist in all eukaryotic organisms. There are three major 
antioxidant enzymes: superoxide dismutase (SOD), catalase and glutathione (GSH) 
peroxidase (Sies, 1993).  All of these enzymes are quite general and they have an effect 
on a broad range of substrates. In addition there are several types of specialized 
antioxidant enzymes that react with and detoxify specific oxidants. 
 
1.3.3 Oxidative stress on proteins 
 
Proteins are a major target for oxidants due to their abundance in the cell; in dried cells 
and in tissue protein constitutes about 70 % of the weight. In addition, proteins have a 
high rate constant for reaction with oxidants (Davies, 2005), especially with singlet 
oxygen (Davies, 2003). Since proteins have several different and specific biological 
functions, oxidative modification of proteins can result in various functional 
consequences. In general, oxidative modifications of proteins may result in reduced 
function, or even loss of their normal function. Some oxidants result in limited and 
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specific damage, while others cause widespread and relatively non-specific damage. 
Generally the most reactive oxidants are the least selective ones (Davies, 2005).   
When proteins are damaged they may become targeted for degradation (Chang 
et al., 2000). Proteolysis down to amino acids is carried out by different endogenous 
proteases and lysosomal pathways (Chang et al., 2000; Stadtman & Levine, 2000). 
Furthermore, it has been shown that protein oxidation occurs very early after cells are 
exposed to oxidative stress and that this oxidation happens before the decrease of 
cellular ATP and the subsequent cell death (Ciolino & Levine, 1997). Different 
oxidative modifications of proteins are involved in different diseases including neuro-
generative disorders and cancer. For a more extensive treatment of this subject, the 
reader is referred to (Berlett & Stadtman, 1997).  
Radical attacks on proteins can generate secondary reactive species ultimately 
resulting in cell death. The propagation of radical reactions on proteins is well known 
and described in (Hawkins & Davies, 2001) and will not be further elaborated upon  in 
this thesis. Consequences of protein oxidation at the cellular level are presented in 
Figure 16, but the focus will be on the different modifications and the role of oxidative 
protein modifications in cellular signalling. There are two main sites of oxidative 
damage on proteins (Berlett & Stadtman, 1997): oxidation of the protein backbone and 
oxidation of amino acid residue side chains. In brief, oxidation of protein backbone 
leads to intra- and inter-protein crosslinking and peptide backbone cleavage (Barelli et 
al., 2008; Berlett & Stadtman, 1997). The side chain oxidation is more complex, as 
described subsequently. 
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Figure 16: A schematic overview of cellular consequences after protein oxidation. The figure is 
adapted from: 
http://scholar.googleusercontent.com/scholar?q=cache:OMuFFKHxkWoJ:scholar.google.com/
&hl=no&as_sdt=0&as_vis=1  which was based on (Davies & Truscott, 2001; Hawkins & 
Davies, 2001). 
 
There are 20 different amino acid side chains when rare amino acids and post 
translational modifications are excluded. Many radicals lack electrons and consequently 
they react preferably with electron-rich side chains (Trp, Tyr, His, Met, Cys and Phe). 
Most of the oxidative modifications on side chains result in increase of hydrophilicity of 
the target residue. The structural effects are displayed Figure 17. Due to the high 
number of potential oxidative reaction sites and products it is practical to divide the 
amino acids into four groups: with cystine and cysteine residues, aliphatic amino acids, 
aromatic amino acids and methionine. The first group will be discussed last and more in 
depth. 
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Figure 17: This figure presents schematically visualized effects of oxidative stress on protein 
structure: A) unfolding (partial or total); B) backbone cleavage; and C) aggregation. The 
unfolding can be reversible, see text 1.3.4. Backbone cleavage may be from direct oxidation or 
indirect due to increased susceptibility to proteolysis. Figure is adapted from(Tornvall, 2010). 
 
Amino acids with aliphatic side chains (glycine, alanine, valine, proline, leucine and 
isoleucine) are oxidatively modified primarily by hydrogen abstraction and the major 
products formed are peroxides, alcohols and carbonyls. These modifications are 
irreversible. The most studied product is probably carbonyls. Carbonylated proteins are 
generally dysfunctional, can be caused by multiple reactions, measured by several 
techniques and may occur in several disease states (Dalle-Donne et al., 2003).  The 
content of carbonylated proteins increases with age and at the end of a life cycle about 
one out of three proteins carries a carbonylation (Stadtman & Levine, 2000). The 
increase in carbonylation is drastic in the last third of a lifespan (in the range of 
C.elegans to human), which usually is after the reproducible phase (Levine, 2002; 
Levine & Stadtman, 2001; Stadtman & Levine, 2000). The importance of keeping the 
carbonylation low during reproducible age is documented  in a plant study where they 
found that the carbonylation increased during life, but was reduced before pollination 
[(Nystrom, 2005) and references therein]. Carbonylation has a role in age related 
diseases as well, probably mostly due to the loss of protein function (Dalle-Donne et al., 
2006a; Dalle-Donne et al., 2006b). At high content, carbonylated proteins are likely to 
cause substantial disruption of cellular function (Levine & Stadtman, 2001).  
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Amino acids with aromatic side chains (phenylalanine, tyrosine, tryptophan and 
histidine) are oxidatively modified mainly through addition, but abstraction can occur. 
Oxidation of aromatic side chains is irreversible. Electron abstraction on aromatic side 
chains results mainly in hydroxylated products. In contrast, addition of electrons results 
in a great diversity of products (since the end product often has incorporated elements 
from the relevant oxidant). The same types of end products seem to be formed both in 
the presence and absence of oxygen (Davies, 2005). 
Methionine residues of proteins are very sensitive to oxidation from any kind of 
ROS/oxidant (Stadtman & Levine, 2000). Oxidation of methionine can be reversed 
enzymatically, unlike the oxidative modifications on non-sulphur-containing amino 
acids. Methionine oxidation results either in methionine sulfone or in methionine 
sulfoxide. Since sulphur centres are easily oxidized, the side chains of methionine and 
cysteine are the main oxidations sites under mild oxidative conditions, while 
carbonylation is more pronounced under severe oxidative stress (Tornvall, 2010). More 
details on methionine oxidation are extensively reviewed in (Davies, 2005). 
 
1.3.4 Cystine and cysteine; thiol proteins 
 
Oxidation of thiol proteins is the main focus in the last manuscript of this thesis. A thiol 
is an organosulfur compound that contains a carbon-bonded sulfhydryl (–C–SH or R–
SH) group (where R represents an alkane, alkene, or other carbon-containing group of 
atoms). The –SH functional group itself is referred to as either a thiol group or a 
sulfhydryl group [http://chemistry.about.com/od/organicchemistryglossary/g/Thiol-
Definition.htm (2015-01-28)]. 
There are three sulphur containing amino acids; cysteine, cystine and 
methionine, but methionine cannot make disulphide bonds. In addition, methionine is a 
thiol-ester due to the methyl group attached to the sulphur. Cystine is a dimeric amino 
acid made up of two cysteine molecules linked by disulphide bond. Oxidation of cystine 
is less studied than oxidation of cysteine and therefore is most of the thiol oxidation 
below equivalent with cysteine oxidation. 
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 Oxidized cysteine residues can exist in a range of specific modifications. The 
main modifications are shown in Figure 18.  Oxidative thiol protein modifications can 
be reversible or irreversible. Sulfinic and sulfonic acid are irreversible modifications 
while intermolecular disulphide, glutathionylation, intramolecular disulphide and 
sulfonamide are reversible thiol modifications. Often the irreversible modifications are 
induced under more severe oxidative stress while the reversible forms are dominating 
under mild oxidative stress (Jacob, 2011).  
 
 
Figure 18: Schematic drawing of the main oxidative modifications of cysteine. The figure is 
adapted from http://groups.mcr.umcutrecht.nl/dansen/.  
 
1.3.5 Detection techniques  
 
Various methods are used within redox proteomics. The diversity in methods reflects the 
diversity of modifications and is in addition influenced by type of consequence 
examined (e.g. loss of function, identification, intermediates and end products). 
Methods to study oxidatively modified thiol proteins often involve labelling, separation 
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and identification. Common techniques are alkylation, labelling with a tag or antibody, 
gel electrophoresis, immune precipitation and mass spectrometry. The current limitation 
in the methods is sensitivity, which implies a high probability that important target 
proteins are lost due to low abundance. For these to be detected an alternative is to 
monitor the redox state of selected of proteins instead of all possibilities. Several 
techniques are well described by others in reviews and articles (Barelli et al., 2008; Baty 
et al., 2002; Bonini et al., 2006; Burgoyne & Eaton, 2011; Burkitt & Wardman, 2001; 
Camerini et al., 2005; Chouchani et al., 2011; Cuddihy et al., 2009; Dalle-Donne et al., 
2006b; Fu et al., 2008; Gartner et al., 2007; Hawkins et al., 2009; Landar et al., 2006; 
Leichert & Jakob, 2004; Riederer, 2009; Rogers et al., 2006; Thamsen & Jakob, 2011; 
Tornvall, 2010; Wardman, 2007; Wardman, 2008) and will not be further described 
here. 
 
1.3.6 Reversible thiol oxidation in cell signalling 
 
Oxidants can both activate and inactivate transcription factors, membrane channels and 
enzymes, and regulate phosphorylation and calcium dependent signalling pathways. The 
controlled oxidation and reduction of cysteine residues constitutes a redox switch 
mechanism which is thought to be the major mechanism for reactive oxidants to 
regulate  cell signalling (Dalle-Donne et al., 2007; Davies, 2005; Dickinson & Chang, 
2011; Hogg, 2003; Janssen-Heininger et al., 2008; Winterbourn & Hampton, 2008). 
Signalling criteria would require the oxidation to be preferential for specific proteins 
and the process should be fast and reversible. Different models that fit  signalling 
criteria are presented by Winterbourn and Hampton (Winterbourn & Hampton, 2008). 
The most important determining factors are probably the rate constant in the reaction 
between the oxidant and the thiol, the reduction potential of the thiol (Epa or ORP) and 
the acid dissociation constant (pKa) for each thiol species, as well as the conformation 
and the abundance of the actual thiol protein (Jacob, 2011).  A low pKa is a key property 
for enhancing the reactivity of a thiol protein (Poole, 2014). Almost all physiological 
oxidants can react with thiol proteins (Winterbourn & Hampton, 2008).  
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A number of mechanisms and enzymes are involved in the redox control of 
reversible thiol modifications. The ability to reverse an oxidative modification is a 
requisite for redox signalling, otherwise there would be no redox regulation. Cleavage 
of the disulphide bond has been reviewed (Hogg, 2003), but it is unclear whether this is 
a general mechanism for controlling protein function or if it is valid for a few selected 
proteins only. Some of the main redox controls for thiol proteins are briefly described 
below and more detailed elsewhere (Holmgren et al., 2005; Riederer, 2009). 
Glutathione (GSH) is an antioxidant which can scavenge free radicals, reduce 
peroxides and bind electrophilic compounds. GSH is the major defence mechanism 
against oxidative and other forms of stress. Glutathione reduces disulphide bonds by 
electron donation, but this process transforms GSH into glutathione disulphide (GSSG). 
The GSH/GSSG ratio can be used as a measure of the oxidative stress level in cells. 
Glutathione disulphide is harmful for the cells and needs to be either transported out of 
the cell or converted by glutathione reductase.  Addition of GSH to a protein is called 
glutathionylation and the mechanism is reviewed in (Dalle-Donne et al., 2011). 
Glutaredoxins are small redox enzymes which are oxidized by substrates and 
reduced non-enzymatically by GSH. Hence, glutaredoxins are responsible for removing 
GSH from glutathionylated proteins (Holmgren et al., 2005).  
Thioredoxins are a family of small redox enzymes which are present in nearly all 
organisms and are involved in many important biological processes. Their function is to 
reduce disulphide bonds in a variety of proteins by cysteine thiol-disulphide exchange 
reactions. Thioredoxins are kept in reduced state by thioredoxin reductase through a 
NADPH dependent reaction (Holmgren et al., 2005). 
 
Thiol based signalling is found in plants, animals and single cell organisms (Wouters et 
al., 2011). Since oxidants act directly on the target, the response is fast. Furthermore, 
adjustment of the response can vary with the different thiol modifications and by 
modification of different thiol residues on the protein. The adjustment is illustrated by 
the triggering of different cellular pathways in response to an increasing level of 
oxidants, as shown in Figure 19.   
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Figure 19: Cells responds to increasing oxidative stress. Different signal pathways are triggered 
at different stress level. H2O2 is often used as oxidant in model systems and here the increasing 
level of H2O2 illustrates increasing oxidative stress level. This figure is adapted from 
http://groups.mcr.umcutrecht.nl/dansen/.  
 
Redox signalling is an important factor in e.g.  inflammatory responses, stem cell 
biology, aging, cancer and cell signalling. The role of reversible oxidation is 
demonstrated on some central proteins. A few of them are listed below with relevant 
references while some redox-regulated proteins that are important in apoptosis will 
subsequently be discussed in more detail. 
Several transcription factors are found to be regulated by redox switches. The 
most studied ones are NF-țB (Leonarduzzi et al., 2011; Oktyabrsky & Smirnova, 2007; 
Pineda-Molina et al., 2001)  and AP-1 [(Leonarduzzi et al., 2011; Oktyabrsky & 
Smirnova, 2007) and references therein]. Other examples are; microbial Yap1p (Brandes 
et al., 2009; Georgiou, 2002; Paget & Buttner, 2003), microbial OxyR (Georgiou, 2002; 
Paget & Buttner, 2003), specificity protein-1 (Sp-1) (Leonarduzzi et al., 2011), Ets-1 
(Leonarduzzi et al., 2011), hypoxia inducible factor-1 (HIF-1) (Leonarduzzi et al., 2011) 
and the mammalian family of fork head box proteins, class O, (FoxO) (Dansen et al., 
2009; Leonarduzzi et al., 2011). 
Protein kinases are known to regulate most of the cellular pathways and 
particularly signal transduction. The protein kinase family can be subdivided according 
to amino acid they act upon. Tyrosine specific kinases often function as growth factor 
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receptors and have a conserved cysteine residue in their catalytic domain that must be 
fully reduced for complete activity [(Gabbita et al., 2000) and references therein]. 
Redox regulation of phosphorylation is reviewed elsewhere (Brandes et al., 2009; 
Chiarugi & Buricchi, 2007; Gabbita et al., 2000; Janssen-Heininger et al., 2008; 
Leonarduzzi et al., 2011; Oktyabrsky & Smirnova, 2007).  
Serine/threonine specific kinases are involved in the regulation of cell 
proliferation, differentiation, apoptosis and embryonic development. Their catalytic 
domain is highly conserved and contains a cysteine rich region. Studies has shown that 
several of these kinases are redox regulated e.g. protein kinase C (PKC) (Leonarduzzi et 
al., 2011), mitogen activated protein kinase (MAPK) family (Cross & Templeton, 2004; 
Gabbita et al., 2000; Giles, 2006; Leonarduzzi et al., 2011) and protein kinase B (PKB), 
also called Akt (Leonarduzzi et al., 2011). 
Phosphatases are enzymes with a mechanism opposite of protein kinases, but 
similarly they contain a cysteine rich region in their catalytic domain. While protein 
kinases are activated by oxidants, phosphatases are transiently inhibited by oxidants 
[reviewed in (Chiarugi & Buricchi, 2007; Leonarduzzi et al., 2011)]. Specific examples 
are cell division cycle 25 (Cdc25) (Leonarduzzi et al., 2011) and PTP1B (Chiarugi & 
Buricchi, 2007; Cross & Templeton, 2004). 
The redox regulation of thiol dependent pathways in cancer has been extensively 
reviewed (Giles, 2006). Often the cancer cells have altered redox homeostasis compared 
to normal cells. Many reviews state that the level of oxidants in cancer cells are elevated 
due to their high metabolism, but this is not definite (Choudhari et al., 2014; Kwee, 
2014; Raninga et al., 2014). Cancer cells readily redox adapts to their environment and 
a tumour can have a range from well oxygenated to hypoxia, and there seems to be a 
difference between cancer stem cells and cancer cells (Acharya et al., 2010; Liou & 
Storz, 2010). However, central factors for cancer development are demonstrated to be 
redox regulated(Parri & Chiarugi, 2013); tumour suppressor protein p53 (Cross & 
Templeton, 2004; Leonarduzzi et al., 2011) and references therein] and nuclear factor 
(erythroid-derived 2)-like 2, also known as Nrf2 (Leonarduzzi et al., 2011; Na & Surh, 
2006; Ray et al., 2012). 
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1.3.6.1 Redox regulation, a mechanism in the apoptotic pathway 
 
Normal oxidant level in cells usually promotes cell proliferation, while a sub-toxic level 
induces apoptosis and toxic levels of oxidants can lead to necrosis and amplification of 
an inflammatory response, see Figure 19. In general, thiol oxidation activates pro-
apoptotic signal pathways and inhibits pathways promoting cell survival.  
Mitochondria are both a ROS-producing organelle and a sensitive oxidant target. 
Furthermore, mitochondria play an important role in apoptosis. The role of 
mitochondrial oxidative stress in apoptosis has been extensively reviewed by others 
(Circu & Aw, 2010; Orrenius et al., 2007). However, a few examples of redox regulation 
of apoptosis will be given below. 
Mitochondrial permeability transition (MPT) occurs when a nonspecific pore 
(mitochondrial permeability transition pore, MPTP) in the inner mitochondrial 
membrane opens. There are several effects of MPT, including release of mitochondrial 
contents, depolarization of the mitochondrial membrane and thereby ATP depletion. 
MPT is a key event in apoptosis, by releasing cytochrome c. One model for pore 
formation is based on the conformational changes on the inner mitochondrial membrane 
transport protein adenine nucleotide translocase (Halestrap et al., 1997; Moran et al., 
2001). The mitochondrial matrix protein cyclophilin-D appears to have a key role in this 
conformational change. Oxidative thiol modification on cyclophilin-D leads to 
increased binding of this protein to the inner mitochondrial membrane and increased 
sensitivity to MPT pore opening (Halestrap et al., 1997; Moran et al., 2001). 
Consequently, MPT seems to be subject to redox regulation, implicating cytochrome c 
release and subsequently apoptosis. 
 Apoptosis signal regulating kinase (ASK1) is a MAPK kinase which activates 
the JNK and p38 pathway in response to several stress factors, including oxidative 
stress. There are several layers of controlling ASK1 and a central contributor is thiol 
oxidation. ASK1 can bind directly to both thioredoxin and glutaredoxin. Both of them 
are part of the redox defence and are easily thiol oxidized. Upon thiol oxidation they 
detach from ASK1 and thereby induce apoptosis. The more detailed mechanism of this 
is reviewed in (Cross & Templeton, 2004). 
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Tumour suppressor PTEN (phosphatase and tensin homologue deleted from 
chromosome-10) directly counteracts the effect of PI3K. Many other phosphatases also 
regulate the PI3K/Akt/mTor pathway negatively. PTEN is redox regulated and is 
important for cellular proliferation. One study has shown that even in absence of growth 
factors, administration of exogenous peroxide is sufficient to oxidize PTEN which then 
activate the PI3K/Akt/mTor pathway (Giles, 2006; Leslie et al., 2003). The membrane-
bound NADPH oxidase Nox 1 is an important source of oxidants for PTEN regulation. 
Furthermore, this oxidoreductase is coupled to PDGF receptor activation resulting in 
ROS activation of PI3K/Akt/mTor, increased proliferation rate and inhibited apoptosis.  
Since Nox 1 is upstream in the pathway, its activation is expected to increase the 
extracellular concentration of oxidants. This could imply that the extracellular 
environment exerts a paracrine regulatory role in cell signalling, as suggested in (Giles, 
2006). 
 
1.3.7 Summary of oxidative stress 
 
PDT induces oxidants and cell death. These oxidants could both damage the cell 
intracellularly and induce reversible oxidation of thiol proteins. Some proteins are found 
to be redox-regulated by reversible oxidation of cysteine residues. Redox signalling is a 
growing field in science. Redox signalling is now recognized to be associated in 
important physiological events, such as apoptosis, cell cycle regulation, proliferation, 
aging, inflammation, cell migration and angiogenesis. 
In redox signalling the oxidation and reduction of cysteine is the most studied 
mechanism and this thiol-based redox switch is also probably the principal mechanism. 
Thiol based signalling is proven to regulate important cellular mechanisms including 
apoptosis. It might turn out that redox signalling is just as important as protein 
phosphorylation is for regulating cellular responses.  
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Aims of the study 
 
ALA-based PDT is in clinical use, but it has a potential for expansion as a clinical 
treatment mode. One of the obstacles of the treatment is the limited uptake of the 
prodrug ALA. HAL is an ester derivative of ALA that can diffuse through the cell 
membrane and it has thereby overcome the uptake obstacle. The thesis concentrates on 
HAL-PDT. 
To further improve the PDT treatment it is important to learn as much as 
possible about the induced mechanisms and how the outcome of the treatment is 
affected when changing a treatment parameter. The irradiation parameters are in 
principle easy to alter and the treatment might be optimized by changing the light 
regimes, wavelength etc.  The thesis concentrates on wavelength, fluence rate and 
fractionation of the delivered light. 
Moreover, PDT generates photochemical reactions leading to oxidative damage in 
the cells. Subsequent cell death should occur after the treatment, preferably only in the 
cancerous cells/tissue. It is important to know details of these oxidative reactions and 
damages leading to cell death. The thesis concentrates on studies of oxidation of 
proteins, an important class of ROS damage. 
 
With these aspects in mind, the main aims of the thesis have been identified and can 
be specified by the following hypotheses: 
 
- Does fractionated light delivery give results different than continuous light 
delivery (paper I)  
- Does wavelength or irradiation affect cell kill efficiency and which cell death 
pathway is triggered (paper II) 
- Does HAL-PDT induce protein carbonylation, PTMs and altered protein 
expression (paper III) 
- Does HAL-PDT induce reversible thiol protein oxidation and could some of 
these be a triggering signal for apoptosis (paper IV) 
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Summary of results 
 
Paper I:  
 
Photo induced hexylaminolevulinate destruction of rat bladder cells AY-27. 
 
HAL-PDD is approved for diagnosis of bladder cancer by blue light cystoscopy. The rat 
bladder cancer cell line, AY-27, is well established as a useful in vivo animal model for 
bladder cancer. In vitro experiments using this cell line may therefore be of value in 
establishing basic photophysical parameters for future treatment of patients. For 
optimizing HAL-PDT in order to take the step from diagnosis to treatment, it is 
important to establish the best possible light protocol. In this study red light was used 
instead of blue light since red light is considered better for clinical treatment due to 
greater penetration depth of red light. 
To establish a dose response curve for AY-27, mitochondrial metabolic activity 
was measured by MTT assay 24 hours after HAL-PDT (10 μM HAL, 3.5 hours, serum 
free, 36 mW/cm2, 630 nm). There was no observable light toxicity and the curve was 
typical sigmoidal as PDT response curves mostly are. This dose response result shows 
that this bladder cancer cell line responds well to red light HAL-PDT. 
To study the induction of apoptosis the Annexin V/PI assay and the YO-PRO-1/PI 
assay were used. Both assays were used at 1h and 24 h after HAL-PDT (same protocol 
as for the dose response, but irradiance at 20 mW/cm2). Using these assays, we 
concluded that the main cell death pathway was necrosis. The maximum apoptotic 
fraction was 10 % measured for a low dose 1 h after PDT (total cell viability 30 %). The 
LD50 measured using the Annexin/PI assay at 1 h after HAL-PDT was substantially 
higher dose than the LD50 measured by MTT 24 h after HAL-PDT.  
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Figure 20: Viable fraction (at 1 h and 24 h) after red light (630 nm, 20 mW /cm2, 5.4 J/cm2) 
HAL-PDT (10mM, 3.5 h) measured by flow cytometry with annexin V/PI assay. MTT assay 
measurements (at 1 h and 24 h) after the same treatment are also shown (a). Apoptotic and 
necrotic fraction (at 1 h and 24 h) after red light HAL-PDT, measured by flow cytometry with 
annexin V/PI assay. The bars represent mean values±SD of 3 independent experiments, each 
done in duplicate (Ekroll et al., 2011). 
 
To test whether fractionation of the light delivery influenced on the outcome, a 
light interval regime of light 45 s/darkness 60 s was used. The fractionation of the 5.4 
J/cm2 (20 mW/cm2) dose gave the same results as continuous light delivery as measured 
both at 1 h and 24 h after the treatment and for both the MTT assay and the Annexin 
V/PI assay. This indicates that fractionation of light delivery with this light/dark interval 
does not influence the outcome. 
 
Paper II:  
 
Red versus blue light illumination in hexyl 5-aminolevulinate photodynamic therapy: 
the influence of light color and irradiance on the treatment outcome in vitro. 
 
Without light there is no PDT. It is fundamental to optimize this treatment parameter for 
an optimal result. The in-house made lamps made it possible to study effects of the 
photophysical parameters wavelength and irradiance. 
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Figure 21: Flowchart of the experiments, the photophysical parameters tested and the cell lines 
used (Helander et al., 2014). 
 
To study whether the irradiance had an effect on total cell death or whether total 
light dose was a determining factor, we measured cell viability for five human cancer 
cell lines at 24 hours after the treatment with different light doses and irradiances. Our 
results indicated that high irradiance is more efficient in killing cells compared to lower 
irradiance at the same total light doses. The efficacy difference between high and lower 
irradiance is cell line specific. For light doses resulting in close to complete cell death 
the difference between high and low irradiance is cannot be distinguished. 
To improve the treatment it is important to know if the protocol in use generates 
only necrosis, only apoptosis or a mix of both cell death pathways. A mix of necrosis 
and apoptosis is favourable since this promotes activation of possible long-term 
immunity and immediate immune responses. One central measurable biochemical 
parameters in the apoptotic pathway is activation of caspase 3. We measured the caspase 
3/7 activity for two of the cell lines, A431 and T24, for different light doses, two blue 
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light irradiances and one red light irradiance. Our results show that which pathway is 
triggered depends on both the cell line and on the photophysical parameters. Red light 
induces higher caspase 3/7 activity than blue light and elicits the highest caspase 3/7 
activity at full doses resulting in complete cell kill. In contrast, blue light has highest 
caspase 3/7 activity at doses resulting in about 85 % cell kill. In addition, low irradiance 
activated visibly more caspase 3/7 activity than high irradiance at the same doses. 
 One important result from this study is the large difference between the five cell 
lines tested. Both the light doses required for cell killing and the shape of the dose 
response curves differ greatly. 
 
Paper III:  
 
Photodynamic therapy with hexyl aminolevulinate induces carbonylation, 
posttranslational modifications and changed expression of proteins in cell survival 
and cell death pathways. 
 
PDT induces photochemical reactions and thereby oxidative stress. Cells have 
mechanisms to respond to oxidative stress and damage and these mechanisms depend 
on proteins. To examine if changes in protein modification could contribute to the effect 
of PDT, the AY-27 cell line was used as a model and HAL-PDT (10 μM HAL, 3.5 h, 
serum free, 12.9 mW/cm2, 435 nm) as treatment. At 2 hours after illumination with 0.45 
J/cm2, which results in approximately 80 % cell kill, the cells were harvested and 
protein extracted for analyses. 
 2D-DIGE measurements of untreated control cells, HAL incubated cells and 
HAL-PDT treated cells demonstrated good reproducibility between experiments and 
that a large number of proteins were up or down regulated. In addition, we observed PI-
shifts for some of the proteins, indicating an enzymatic modification of the protein. To 
be able to identify some of these altered proteins, a 2D-gel with much higher protein 
sample content was run and gel spots was picked based on the 2D-DIGE results. From 
this a total of 40 proteins were identified. Most of these proteins displayed an acidic PI-
shift, indicating altered phosphorylation status or oxidative thiol modifications. Notably, 
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these proteins mostly belong to mitochondria/ER molecular chaperones and stress 
response proteins. 
 
 
Figure 22: Mapping of 40 identified proteins in HAL-PDT treated AY-27 cells (Baglo et al., 
2011). 
 
Carbonylation is a permanent type of oxidative damage of proteins. Carbonylation does 
not induce PI-shift in 2D-DIGE gels so to identify carbonylated proteins, control cells 
and HAL-PDT treated cells were derivatized by DNPH, immunoprecipitated and 
separated by 2D-GE. From this experiment, 9 proteins were identified (by MS) to have 
increased carbonylation after HAL-PDT and one decreased. 
The results from the 2D-DIGE and 2D-GE analyses were launched into 
PHANTER classification system to see if specific mechanisms were targeted by HAL-
PDT. The majority of the identified proteins belonged to mitochondria, ER and 
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membranes, but the overall picture is that HAL-PDT induces changes in a large number 
of proteins involved in diverse functions.  
  
Paper IV – manuscript  
 
Reversible oxidation of thiol proteins after hexylaminolevulinate mediated 
photodynamic therapy. 
 
The photochemical reactions generated from PDT will induce oxidants that can induce 
oxidative modifications and damage on cellular targets. Proteins are a major target due 
to their abundance and reactivity with oxidants. Most of the protein modifications are 
irreversible, although modifications on the thiol group on Cys residues are reversible. 
This is now recognized as a signalling mechanism and the knowledge about its 
significance is increasing (Poole, 2014; Popov, 2014; Reczek & Chandel, 2014; Sies, 
2015).  To examine if this type of modification was induced by HAL-PDT and possibly 
contributing to induced cell death, we used the human cancer cell line A431 as model 
system.   
Red light HAL-PDT resulted in a sigmoidal dose response curve at 24 h after the 
treatment as expected, but the induction of apoptosis did not decrease as expected for 
the highest doses. At 12.5 J/cm2 complete cell kill was measured at 24 h and the 
apoptotic fraction was 40 %. This dose was used for the proteomic study and the cells 
harvested 30 min post HAL-PDT. 
The reversibly oxidized thiol proteins were enriched and then identified by LC-
MS/MS. Over 1900 proteins were identified, about a third of them were also found in 
the untreated controls as well. The proteins that were found in at least two treated 
samples, but not in controls, and above an ID confidence threshold, were further 
analysed (283 proteins, HAL-PDT list).  The proteins identified in this way were 
mapped to several cellular compartments, and mitochondria were not the major 
localization as expected. Their cellular function was compared to the ‘normal percent’ 
distribution (in IPA). Interestingly, the largest differences were observed within cellular 
homeostasis and cell cycle.  
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Figure 23: Venn diagram shows the overlap between our HAL-PDT list [blue], two 
databases for redox regulated proteins (dbGSH and RedoxDB) [yellow] and proteins 
known to be a part of cell death pathways (Cell Death Proteomics) [red].  
 
Furthermore, 135 proteins from the HAL-PDT list are associated to programmed 
cell death according to the database Cell Death Proteomic. In the databases RedoxDB 
and dbGSH proteins with reported Cys residue oxidative modification (mostly S-
gluthationylation) are manually assembled and 65 out of the HAL-PDT list proteins are 
found in these two databases. Out of these proteins, 50 were common in the HAL-PDT 
dataset, the redox databases and in the cell death database. We did a manual literature 
search to see if any of these were reported to be redox regulated. Two important redox 
regulated apoptosis proteins in this list were the 14-3-3 protein family (6 out of 7 
isoforms in HAL-PDT dataset) and the kinase c-Src.  
Further studies are needed to elucidate to what extent the identified proteins in 
HAL-PDT set are involved in redox-regulation of treatment-induced cell death 
signaling. 
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General discussion 
 
The current status of PDT within oncology and its future perspectives have been well 
reviewed (Allison, 2014). A general discussion of the focus areas in this thesis follows 
in the subsequent text. 
 
Photophysical parameters 
 
Light is one out of three essential factors in PDT (light, PS and oxygen). It is easy to 
monitor the light, which is therefore amenable to optimization for PDT treatment. For 
optimizing this factor is it important to know how the different photophysical 
parameters affect the treatment outcome. A real improvement for PDT in general would 
be to monitor the bleaching/fluorescence from the applied light to do a real time actual 
dosimetry and thereby personalize the treatment. The development of improved light 
sources and sensors in combination with increased knowledge about the effect of 
photophysical parameters can make this a reality in the future. In two of the papers 
included in this thesis, Paper I and Paper II, photophysical parameters have been 
studied.  
 
From paper I it looked like blue light HAL-PDT and red light HAL-PDT were about 
equally cytotoxic when taking into account the theoretical difference between PpIXs 
absorption capacity at those two wavelengths. In paper II the PpIX absorption spectrum 
was measured for T24 and A431 cells. The absorption ratio between the two 
wavelengths used in this study (410 nm: 624 nm) was 56 and this ratio correlated well 
with the cell killing efficiency for the two wavelengths, supporting the presumption 
from paper I.  PSs based on porphyrin (including PpIX) can in principle be activated by 
blue, green and red light. In theory could the wavelength for clinical PDT application be 
chosen based on the wanted qualities, the assumption of wavelength independence for 
inducing cytotoxicity is supported by the results in paper I and II.   This may be 
exploited by clinicians to administer light at different depths (although limited) to 
optimize the treatment, thus will information on cytotoxicity and mode of killing by 
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different wavelengths may be useful.  
 
Cell cytotoxicity after PDT seemingly comprises apoptosis and necrosis as major death 
modes. To what extent the induction of the two pathways is influenced by applied 
wavelength and irradiance was studied in paper II. The results indicated that both 
wavelength and irradiance had an impact on which cell death pathways that was 
induced. It is important to have knowledge about which pathway that will be induced 
from the treatment, since they may trigger different additional responses. Necrosis alone 
can damage surrounding healthy tissue while tissue damage from apoptosis alone will 
be restricted. From this point of view apoptosis is preferable. However, due to the 
additional responses, PDT is not only a local treatment. Necrosis can release cell debris, 
immunogenic proteins and cytokines from the tumour cells. This causes up-regulation 
of the immune system and apoptosis and triggers the innate immune system to 
phagocytose. This combination can lead to a successful presentation of tumour 
associated antigens in the adaptive immune system, thus creating long term immunity in 
addition to the immediate immune response from necrosis, and that this has potential as 
“cancer vaccine”(Panzarini et al., 2013). Therefore, optimizing the photophysical 
parameters to achieve high cytotoxicity and inducing a mix of apoptosis and necrosis to 
achieve both immediate and long term immune response should be the goal. 
 
The effect from fractionation of  light delivery in ALA-based PDT has been studied  by 
e.g. (Ascencio et al., 2008; Babilas et al., 2003; de Bruijn et al., 2013; de Bruijn et al., 
2006; Iinuma et al., 1999; Middelburg et al., 2013; Oberdanner et al., 2005). In paper I 
we tested if an interval of 45s light/ 60 s darkness altered the cytotoxicity or percent 
apoptosis when applying blue light HAL-PDT on AY-27 cells. For a dose resulting in 
50 % cell death there was no difference between the outcomes from fractionated light 
delivery compared to continuous light delivery in our study. Most other fractionation 
studies have been done in vivo and they either show improved PDT effect (Ascencio et 
al., 2008; Iinuma et al., 1999; Middelburg et al., 2013) or ambiguous effects (Babilas et 
al., 2003; de Bruijn et al., 2006). For other in vitro fractionation studies the effects of 
fractionation was not consistent, possibly due to different duration of the dark period. 
Oberdanner et al showed decreased cytotoxicity and decreased ROS induction with light 
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intervals similar to those used in paper I, while de Brujin et al found that a 2 h dark 
period increased the effect of PDT. If the dark period should be long or short remains 
unclear and requires further studies. Short repeated intervals of light may utilize the 
available oxygen in the surroundings by letting oxygen diffuse into the treatment area 
during the dark period and short fractionation reduces the fluence rate. While a longer 
dark period e.g. 2 h makes the cells sensitive to a second round of irradiation. The 
deoxygenation issue can probably be neglected in in vitro studies, so an effect of 
fractionation in these studies is likely to have another cause. The possible optimization 
of PDT by applying light in intervals is probably best studied in vivo. 
 
Cell death pathways  
 
In many PDT articles the subject cell death pathway, e.g. apoptosis, autophagy and 
necrosis, is a part of or is the main focus of the study. Paper I, paper II and paper IV in 
this thesis is no exception.   
As mentioned in the previous paragraph the combination of apoptosis and 
necrosis could result in long time immunity against the treated cancer form (Korbelik & 
Sun, 2006). This prospect of PDT is an area of fast growing interest. The additional 
effect from activated immune system could constitute the difference between complete 
clinical regression and unsuccessful treatment.  
 By gaining knowledge about central mechanisms for effecting, or even better, to 
know the exact triggering mechanism for the cell death,  makes it possible to enhance 
the effect by additional treatment [reviewed in (Agostinis et al., 2011), e.g. enhancing 
PpIX accumulation in tumours by adding vitamin D3 (Anand et al., 2011). Several 
apoptosis-modulating factors have been shown to enhance the PDT mediated cell death 
(Choi et al., 2014; Ferrario et al., 2005; Ferrario et al., 2007; Kessel, 2008; Kessel et al., 
2012; Korbelik et al., 2011; Sarissky et al., 2005; Weyergang et al., 2009). When 
engineering apoptosis modulating factors it is important to keep in mind the 
complicating issue of cross talk between the different cell death pathways (Jain et al., 
2013).  
A possible enhancement factor for PpIX-PDT is the peripheral benzodiazepine 
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receptor (PBR), also called translocator protein (TSPO) [reviewed in (Buytaert et al., 
2007)]. HAL-PDT is demonstrated to target PBR (Furre et al., 2005) and PBR is a 
putative component of the MPT pore amongst other roles in cell function 
(Kolodziejczyk, 2015). A strengthening of PBR mechanism/pathway could optimize 
PpIX-PDT. 
 
Oxidative protein modifications  
 
We have measured induction of ROS in AY-27 cells as a function of light dose in blue 
light HAL-PDT, unpublished results (Figure S1, Supplementary to paper IV). This 
result clearly shows that the amount of induced ROS increases with increased light 
dose. And, pilot studies done in Salzburg shows that the same applies for red light HAL-
PDT on A431 cells. Proteins are major target for the induced oxidants and two types of 
oxidative modifications has been studied in this thesis, carbonylation in paper III and 
reversible thiol modification in paper IV.  
 Carbonylation of proteins is irreversible and frequently results in loss of protein 
function. It is regarded a major hallmark of oxidative damage and is central in aging and 
age related diseases (Cabiscol et al., 2014; Dalle-Donne et al., 2006a; Dalle-Donne et 
al., 2006b; Dalle-Donne et al., 2003; Fedorova et al., 2014). Whether carbonylation is 
involved in signalling pathways, such as antioxidant biology and cellular homeostasis, 
is debated and there exist few studies on the subject (Curtis et al., 2012). The role of 
carbonylation might change during the life cycle of an organism. Presently, 
carbonylation is mostly used within PDT research as an indirect measure of oxidative 
stress. 
 The research field of redox proteomics and its role in signalling is gaining 
interest (Sies, 2015). A PubMed search (24.01.2015) on the terms “redox proteomics” 
resulted in 1633 entries and by adding the term “photodynamic” the number of entries 
decreased to 2. These numbers illustrate the novelty of redox proteomics within PDT. 
The role of redox signalling is briefly described in 1.3.6, but the overall comprehension 
is that redox signalling is a mechanism that is neither only harmful nor only protective 
(Holmstrom & Finkel, 2014). It seems likely redox signalling has an important role in 
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redox homeostasis (Groitl & Jakob, 2014; Ray et al., 2012; Schieber & Chandel, 2014) 
and that its extent in cell death increases (Allen & Mieyal, 2012; Chiu & Dawes, 2012; 
Circu & Aw, 2010; Lee et al., 2012; Navarro-Yepes et al., 2014; Trachootham et al., 
2008; Wang et al., 2012). The role of redox signalling in PDT efficacy is quite 
unexplored. Paper IV in this thesis is a contribution to this topic and will hopefully 
evoke curiosity of other researchers to follow up the topic. To identify a likely trigger 
mechanism and point of no return mechanisms in cell death require more studies. 
Available state-of-the-art technology makes the required studies possible (Ckless, 2014; 
Couvertier et al., 2014; Huang et al., 2014; Panis, 2014; Paulech et al., 2013). 
 
The clinical future for HAL-PDT  
 
The discussion above applies to PDT in general, including HAL-PDT. In this section the 
focus will be on HAL-PDT and its possibilities as clinical treatment. Only the 
application areas and improvements that seem most likely according literature search 
are discussed below. 
 
HAL-PDD is already approved for blue light cystoscopy diagnosis of non-muscle 
invasive bladder cancer under the name Cysview (US) and Hexvix (Europe) (Babjuk et 
al., 2013; Oosterlinck et al., 2004; van der Meijden et al., 2005). The use of HAL-PDD 
as diagnostic tool may improve the diagnosis and treatment of other superficial cancer 
forms as well, e.g. intestinal cancer. Since HAL-PDD gives immediate diagnostic 
outcome, thus anxiety during the waiting period for outcome of the biopsy may be 
avoided. Furthermore, fluorescence-guided resection of tumour tissue will minimize 
normal tissue loss, improving the functional and cosmetic outcome. This may be 
especially important in head and neck surgery. In addition, further irradiation after 
tumour tissue removal could improve eradication of potential remaining tumour cells.  
 
The World Health Organization has pointed out drug resistant microbes as major threat 
to human health (Cars et al., 2008). ALA-based PDT was found to inactivate a broad 
range of microbes, including drug resistant strains [reviewed in (Harris & Pierpoint, 
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2011)]. ALA uptake is energy dependent, while HAL can diffuse through membranes, 
this is one thing making HAL an interesting alternative for inactivation of microbes 
(Yung et al., 2007). Two highly relevant applications are wound healing and inactivation 
of multidrug resistant bacteria. ALA-PDT shows promising results against multiresistant 
staphylococcus aureus (Fu et al., 2013; Li et al., 2013). 
 
The technical development of new light sources enlarges the possible clinical use of 
PDT. A new and interesting light source for PDT are the organic light emitting diodes 
(OLED) (Minaev et al., 2014). These can be used as a light emitting patch and thereby 
as an ambulatory treatment diminishing the clinic time. Attili and co-workers carried out 
an open pilot study treating Bowens disease and superficial basal cell carcinoma (BCC) 
patients with good curing rate and less pain compared to routine PDT (Attili et al., 
2009).  Another relevant light source for minimal clinic time is daylight (Enk et al., 
2014; Fai et al., 2014; Kellner et al., 2014; Neittaanmaki-Perttu et al., 2014; Perez-Perez 
et al., 2014; Rubel et al., 2014; Togsverd-Bo et al., 2014; Togsverd-Bo et al., 2013; 
Wiegell et al., 2012a; Wiegell et al., 2013a; Wiegell et al., 2013b; Wiegell et al., 2012b). 
HAL-PDT cannot easily be overdosed due to the photobleaching of PpIX. This makes 
HAL-PDT especially well-suited for daylight PDT.  
 
HAL-PDT is closer to being an approved clinical treatment within some medical fields. 
Some studies, including clinical trials, show promising results for HAL-PDT on cervical 
cancer (Guyon et al., 2014; Hillemanns et al., 2015; Hillemanns et al., 2014a; 
Hillemanns et al., 2014b) and on bladder cancer (Bader et al., 2012; Bader et al., 2013; 
Lee et al., 2013). ALA and MAL-PDT is already in clinical use within dermatology with 
good results (Christensen, 2013; Ericson et al., 2008; Rkein & Ozog, 2014; Wang et al., 
2015). A few studies indicate that HAL-PDT is at least well suited within dermatology 
as MAL and ALA (Togsverd-Bo et al., 2012a; Togsverd-Bo et al., 2012b; Togsverd-Bo 
et al., 2010).  
 
The perhaps biggest challenge for HAL-PDT on patients is their sensation of pain 
during irradiance and shortly after. This challenge applies to MAL- and ALA-PDT 
patients as well, as described in some studies e.g. (Attili et al., 2011; Chaves et al., 
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2012; Halldin et al., 2011; Halldin et al., 2013; Steinbauer et al., 2009; Warren et al., 
2009). In one study, incubation with HAL induced less pain during illumination than 
incubation with MAL(Yung et al., 2007). Reducing the fluence rate, cooling the treated 
area or using an anaesthetic is actions that can reduce the pain, but for some patients the 
pain is so severe that the treatment must be aborted. The pain inducing mechanism is 
undefined. If the pain challenge is solved successfully, the implementation of HAL-PDT 
on patients will be much easier.  
 
The last and perhaps most important factor for PDT (including HAL-PDT) to achieve 
more clinical use are to increase the number of phase 3 trials. To speed up this process it 
is important that research at the cellular level is carried out with the patients in mind. 
This could pave the way from cells, to animal models, to clinical trials and make 
studies, hopefully, better and time saving.  
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Photodynamic therapy (PDT) is of increasing interest as a relevant treatment for human urinary
bladder cancer. In the present experiments, the rat bladder transitional carcinoma cell line AY-27 was
used as a model to study cell destruction mechanisms induced by PDT. Red LED light (630 nm) PDT
with hexylaminolevulinate (HAL) as precursor for the photosensitizer protoporphyrin IX (PpIX) was
used in treatment of the cells. Flow cytometry with ﬂuorescent markers annexin V, propidium iodide
and YO-PRO-1, as well as MTT assay and confocal microscopy, were used to map cell inactivation
after PDT. Dark toxicity of HAL alone was low in these procedures and LD50 (24 h, MTT assay) was
approximately 1.6 J cm-2 for standard red light (LED) irradiation (36 mW cm-2). Measurements done
1 h after HAL-PDT showed a maximum apoptotic level of about 10% at 6 J cm-2, however the
dominating mode of cell death was necrosis. Forward light scattering indicated an increase in cell size at
low doses, possibly due to necrosis. Survival curves had a dual-slope shape, a ﬁt to single hit,
multi-target approximation gave a parameter estimate of n = 10 and D0 about 2.6 J cm-2. Replacing
continuous light with fractionated light delivery (45 s light/60 s darkness) did not affect the treatment
outcome.
Introduction
Urinary bladder cancer causes more than 130 000 deaths ev-
ery year worldwide1 and 90% of these are caused by transitional
cell carcinomas (TCC).2 The strongest known risk factor for
bladder cancer is smoking, probably due to the high content
of carcinogenic acrylamides in cigarette smoke.2 Treatment of
bladder cancer depends on the stage of the disease, the type of
cancer, and the patient’s age and general health condition. So far,
treatment options have included surgery, endoscopic resection,
chemotherapy and immunotherapy.
Photodynamic therapy (PDT) is a potential treatment modality.
This therapy is based on photochemical reactions between a
photosensitizer and light, where the photosensitizer accumulated
in cancerous tissue is activated by light of an appropriate
wavelength.3–5 This can in turn induce cell death by the production
of singlet oxygen and other reactive oxygen species.6–8 Since cancer
cells have higher accumulation of photosensitizer than normal
cells, PDT is a selective treatment modality.9–12 In order to achieve
curative treatmentwithPDT, it is crucial to ﬁnd the correct balance
between the drug and light doses to destroy cancerous tissue and
avoid irreparable damage to surrounding tissues.13
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Optical spectroscopy is commonly used for both detection and
diagnosis in medicine,14 including the case of superﬁcial urinary
bladder cancer. In a recently published paper by Larsen et al.,13 in
vivo reﬂectance and ﬂuorescence spectroscopy were used on a rat
bladder cancer model. The combined methods can, for example,
predict the therapeutic efﬁcacy of PDT. In the present report,
different spectroscopy techniques and ﬂuorescent markers will,
likewise, be used to study cancer cell destruction mechanisms.
Superﬁcial urinary bladder cancer is potentially well suited for
effective treatment by PDT because the bladder is easily accessible
for both intravesical instillation and illumination. Intravesical
instillation, i.e. direct injection of a photosensitizer into the
bladder, has been shown to cause less damage tonormal tissue than
intravenous injection, while still giving the same PDT efﬁcacy.15 A
number of photosensitizers are currently available for PDT, among
which 5-aminolevulinic acid (ALA) is often preferred. ALA
derivates such as hexylaminolevulinate (HAL) can increase the
efﬁcacy of PDT due to higher lipophilicity, which leads to better
penetration into cells and ultimately a higher concentration of the
acting photosensitizer protoporphyrin IX (PpIX).16–18 Moreover,
HAL is approved for bladder cancer diagnosis in the EU, EEA
countries and the US.19
PDT can induce apoptotic and necrotic cell death both in vivo
and in vitro. The balance between apoptosis and necrosis following
different doses of ALA-based PDT is not fully understood, but
may be important in a clinical setting. The aim of this work is
to study the modes of cell death following hexylaminolevulinate
mediated photodynamic therapy (HAL-PDT) of rat bladder
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transitional cell carcinoma cells (AY-27), a cell type of clinical in-
terest and relevance. The cell destruction processes are investigated
using ﬂow cytometry, confocal microscopy and measurements of
mitochondrial activity. These techniques are also used to study
effects of fractionated or pulsed light delivery versus continuous
light delivery in the PDT process.
Materials and methods
Chemicals
RPMI-1640 medium, L-glutamine, foetal bovine serum (FBS),
phosphate buffered saline (PBS), Accutase, Hepes and 3-(4,5
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT)
were obtained from Sigma Chemicals Co. (St. Louis, MO, USA).
Annexin V Fluos (annexin V) was purchased from Roche Applied
Science (Basel, Switzerland). Quinolinium, 4-(3-methyl-2[3H]-
benzoxazolylidene)methyl)-1–1(3-(triethylammonio)propyl) dii-
odide (YO-PRO-1) were from Invitrogen (Carlsbad, CA,
USA). Propidium iodide (PI) was obtained from Fluka (Sigma
Aldrich Schweiz, Buchs SG, Switzerland) when used with
annexin V and from Invitrogen when used with YO-PRO-1.
Hexylaminolevulinate (HAL) was kindly provided by Photocure
ASA (Oslo, Norway).
Cell culture
The AY-27 cell line, generously supplied by Professor Steven
H. Selman (Medical College of Ohio, Toledo, USA), was grown
in RPMI-1640 medium supplemented with 10% v/v FBS and L-
glutamine (for a total of 0.7 mM), referred to as regular cultivation
medium. The cells were kept in a Binder incubator at 37 ◦C with a
humidiﬁed atmosphere containing 5% CO2 and subcultured twice
a week.
Light conditions
An Aktilite lamp, model CL-128 from Photocure ASA, Oslo,
Norway, (peak intensity at 630 nm) was used as red light (LED)
source in the photodynamic experiments. The lampwas situated in
a room holding a temperature of 37 ◦C. A housing with a diffuser
plate (white glass) on top gave a constant irradiance over an area
larger that two Petri dishes. When establishing the ﬁrst survival
curve the irradiance was 36 ± 1 mW cm-2, in the subsequent exper-
iments the irradiance was lowered to 20 ± 1 mW cm-2 (LI-COR
quantum detector, type LI-190SA, LI-COR Corporate Ofﬁces,
Lincoln,Nebraska,USA). Photosensitized cells and light sensitive
solutions were shielded from light with aluminium foil and the
experiments were performed with minimum of ambient light.
Photodynamic experiments
Cells were seeded in Petri dishes (r = 3 cm, Nunc) two days prior
to PDT at a density of 1.5 ¥ 104 per ml, giving a total of 6 ¥
105 cells ideally, using regular cultivation medium. On the day of
the PDT experiment, a sterile stock solution of HAL (10 mM)
was made by dissolving HAL powder in PBS (pH 6.0) before
sterile ﬁltration (22 mM). The cells were washed once with PBS
and incubated (37 ◦C) in medium containing HAL (10 mM, 3.5 h)
but without FBS. Serum free medium was used during HAL-
incubation to avoid porphyrin excretion to the culture medium.20
The cells were washed twice with PBS, before red light exposure
(630 nm, 20 mW cm-2). After irradiation, cells were incubated (1 h
or 24) in regular cultivation medium before further measurements.
Samples receiving neither HAL nor light served as controls.
Samples receiving only HAL constituted dark toxicity controls.
Controls were otherwise handled as treated samples.
Mitochondrial dehydrogenase assay (MTT assay)
TheMTTassaymeasuresmitochondrial activity, and is commonly
used to make dose-response curves when cell survival is studied.21
Cells were washed with PBS 1 h or 24 h after PDT and
further incubated (1 h, 37 ◦C) in freshly prepared MTT-solution
(2 ml, 0.5 mg ml-1 MTT in regular cultivation medium, 37 ◦C).
The MTT-solution was carefully removed before isopropanol
(2 ml) was added, and the dishes were placed on a plate shaker
(500 rpm, 30 min) for solubilization of the formazan crystals.
The colored solution was transferred to tubes and centrifuged
(1500 rpm, 5 min). The absorbance of the crystal free supernatant
at 588 nm was measured immediately using a Shimadzu UV-
160 IPC spectrophotometer for deciding the cell survival after
treatment.
Flow cytometry using the ﬂuorescence markers annexin V and
propidium iodide
Cells were detached using accutase (3.3ml, 15-20min, 37 ◦C) 1 h or
24hafter PDT.Accutasewas used for cell detachment since trypsin
has been reported to be inefﬁcient after PDT.22–23 The detached
cells were centrifuged (3 min, 1300 rpm) and incubated in Hepes
buffer (12 min, 20 ◦C) containing annexin V and PI according
to the manufacturer’s instructions. The samples were immediately
analyzed in a ﬂow cytometer (LSR-1, Becton Dickinson) with a
488 nm excitation laser line. Fluorescence emission was evaluated
by a 530 ± 28 nm band pass ﬁlter for annexin V and a 660 ± 13 nm
band pass ﬁlter for PI. The resulting data was exported to the
software MATLAB (The MathWorks Inc.) for processing.
Flow cytometry using the ﬂuorescent markers YO-PRO-1 and
propidium iodide
Cells were detached using accutase (3.3 ml, 15–20 min, 37 ◦C) 1 h
or 24 h after PDT and centrifuged (3 min, 1300 rpm). Further
handling was performed on ice. Cell pellets were resuspended in
PBS (1 ml, 4 ◦C) containing YO-PRO-1 (1 ml) and PI (1 ml) and
incubated on ice (25min). The samples were immediately analyzed
in a ﬂow cytometer as described in the previous subsection.
Confocal microscopy
Both pairs of ﬂuorochromeswere also used in confocalmicroscopy
studies (Leica TCS SP5, with objective Universal 50.0 ¥ 0.80) of
the AY-27 cells after HAL-PDT. A 458 nm laser line was used for
excitation, and ﬂuorescence emission was evaluated by band pass
ﬁlters of 500–550 nm and 650–720 nm for annexin V/YO-PRO-1
and PI respectively.
Comparison of continuous and fractionated light delivery
The LD50 dose determined 1 h post PDT (5.4 J cm-2, 270 s)
was used in the comparative studies. Fractionated light (630 nm,
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20 mW cm-2) was delivered in intervals of 45 s separated by 60 s
of darkness. Both the MTT assay and ﬂow cytometry with the
Annexin V/PI assay were used to analyze the treatment outcome.
Hit theory
The experimental survival curve was ﬁtted (least square method)
to a single hit, multi-target model.24 The following expression was
thus applied:
Sf = 1 - (1 - exp(-D/D0))n,
where Sf is the fraction of surviving cells when the dose D is
administered. The calculated dose D0 and the exponent n give
estimates related to the shoulderwidthof the survival curve and the
number of targets necessary to hit before killing a cell, respectively.
Statistical analysis
Data are presented as the mean value from all experiments ±
standard deviation (SD).
Results
Cell survival
Exposing cells incubated with HAL (10 mM, 3.5 h) to red light
(630 nm, 36 mW cm-2) produced the survival curve in Fig. 1.
Incubation with HAL but with no irradiation resulted only in
about 5% reduction of the cell survival, thus showing that the dark
toxicity of HAL was small in the applied procedure. Cell survival
without HAL incubation was measured in separate experiments
and was not inﬂuenced by illumination alone. The LD50 value
was approximately 1.6 J cm-2 in the applied procedure and was
achieved after 45 s of irradiation. An irradiation period of 2.5 min
equals the LD70. During relatively high light doses (10–32 J cm-2)
approximately 99% of the cells were killed. There were no further
changes in survival values when the dose was increased up to
64 J cm-2 (data not shown).
The images in Fig. 2 are results from confocal microscopy
experiments 1 h post HAL-PDT where the ﬂuorescent markers
annexin V (green color) and PI (red color) were used on controls
(a) and PDT treated cells (b). The density plots (Fig. 2c and 2d)
from ﬂow cytometry clearly show a distinctly different pattern for
the two situations. Cells classiﬁed as viable are in the lower left
corner showing little ﬂuorescence from neither annexin V nor PI,
indicating an intact cellmembranewith no display of phosphatidyl
serine (PS) on the outer membrane surface. Apoptotic cells
are clustered in lower right corner displaying high annexin V
ﬂuorescence and little PI ﬂuorescence, indicating an intact cell
membrane with PS present on the outer surface which is an early
hallmark of apoptosis. Necrotic and late apoptotic cells are in the
upper right corner displaying high ﬂuorescence of both annexin V
and PI, indicating a permeable outer membrane.
The fraction of viable cells was determined for different
treatment doses, seen in Fig. 3a. The determinations were done 1 h
after treatmentwithHAL (10mM,3.5 h) and light (630 nm, 20mW
cm-2). The shape of the survival curve allowed a comparison with
PDT survival curves reported for other cell types. Using hit theory,
we could get an estimate of the number of targets in the cells. The
parameters in the model were found by ﬁtting the single hit, multi
Fig. 1 Cell survival as measured by MTT 24 h after red light (630 nm,
36 mW cm-2) HAL-PDT (10 mM, 3.5 h). Without incubation with HAL,
the cells show no response to illumination.
target equation to the data points obtained, using a nonlinear
least squares approach. When all data points were considered to
have equal weight, the estimated parameter values were (with 95%
conﬁdence intervals) n = 10 (0, 21) and D0 = 2 (1.1, 2.6) J cm-2.
The result is depicted in Fig. 3b.
Modes of cell death
The apoptotic fraction (green curve in Fig. 3a) is nearly constant
(4%) in dose range between 0–4 J cm-2 and settles at its maximum
level (10%) already at 6 J cm-2. The necrotic fraction (blue curve)
rises rapidly with increasing dose, reaching 10% at 2.4 J cm-2,
50% at about 6 J cm-2. In samples having received doses higher
than 12 J cm-2, necrosis dominates, as more than 80% of the cell
population is classiﬁed as necrotic. In this dose range, the viable
fraction is decreased below 5%.
The curves seen in Fig. 3 were based on ﬂow cytometry
experiments performed with annexin V/PI assay. HAL-PDT
outcome studied by an alternative ﬂuorochrome pair, YO-PRO-
1 and PI, gave similar results in the tested dose range (data not
shown).
Forward light scattering
The forward light scattering (FSC) was also recorded during all
ﬂow cytometry experiments. Averaged FSC signals are plotted
in Fig. 4 as a function of light dose. For small doses the FSC
signal increases with increasing dose until it passes its maximum
at 2.5 J cm-2 after which the signal strongly decreases. The FSC
signal is usually interpreted as a coarse measure of the size of the
cells, and will be discussed later.
Continuous vs. fractionated light delivery.
The LD50 dose determined by ﬂow cytometry 1 h after treatment
was 5.4 J cm-2 with continuous light delivery, corresponding
to 270 s of light exposure (630 nm, 20 mW cm-2). As seen in
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Fig. 2 Confocal microscopy image of untreated AY-27 cells (a). Confocal microscopy image 1 h after red light (630 nm, 20 mW cm-2) HAL-PDT (10 mM,
3.5 h), using a light dose of 1.8 J cm-2 (b). Density plot from ﬂow cytometry of untreated cells (c). Density plot from ﬂow cytometry 1 h post red light
HAL-PDT, using a light dose of 6 J cm-2 (d). The colours in density plots range from blue (lower density) towards red (higher density).
Fig. 5a, exposing the cells to the same dose, but in light/dark
intervals of 45/60 s produced the same amount of cell death as
the continuous light delivery. TheMTTassay conﬁrmed the results
from ﬂow cytometry; there was no difference between fractionated
and continuous light delivery. Measurements of cell survival 24 h
after treatment also produced identical results for continuous and
fractionated light delivery in both experimental methods (MTT
assay giving lower survival fractions in both cases). No changes in
the amount of apoptosis or necrosis were observed when the two
modes of light delivery were compared (Fig. 5b).
Discussion
Cell survival
Speciﬁc studies on bladder cancer cells are scarce and for the AY-
27 cells only a limited amount of PDT data is reported. But the
LD50 (24 h, MTT assay) value of 1.6 J cm-2 obtained in this study
using red light at 630 nm with 36 mW cm-2 can be compared to
experiments using 435 nm blue light at 13 mW cm-2 (unpublished
data). An LD50 value of 0.4 J cm-2 was obtained after blue light
HAL-PDT of AY-27 cells. Since absorption by PpIX is about
3 times more efﬁcient at 435 nm than 630 nm (in ethanol solution)
these two LD50 values seem to correspond well. Both LD50 values
are found using the MTT assay 24 h after identical treatment
protocols. This indicates that the difference in dose response curves
for blue and red light HAL-PDT on AY-27 cells is accounted for
by the difference in PpIX absorption of red and blue light alone.
Two survival curves are presented in this work (Fig. 1 and red
curve in Fig. 3a). While the curve obtained from ﬂow cytometry
one hour after treatment clearly have a shoulder region, this is
not as evident in the curve obtained from MTT measurements
24 h after treatment. The survival curve established with the MTT
assay using an irradiance of 36 mW cm-2 was very steep, and it
was therefore chosen to operate with a lower irradiance (20 mW
cm-2) in the subsequent ﬂow cytometry experiments.
The ﬂow cytometry procedure requires suitable detachment of
cells after treatmentwithPDT, ideally not inﬂuencing theoutcome.
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Fig. 3 Cell death 1 h post red light (630 nm, 20 mW cm-2) HAL-PDT (10 mM, 3.5 h), measured by ﬂow cytometry with annexin V/PI assay (a). Fitted
survival curve (b). Circles represent mean values ± SD from four separate experiments, each with two parallels.
Fig. 4 Average FSC signal from ﬂow cytometry measurements as a
function of light dose, 1 h post red light (630 nm, 20 mW cm-2) HAL-PDT
(10 mM, 3.5 h).
Accutase was used in this step, as trypsin has been reported to be
inefﬁcient after PDT22–23 (conﬁrmed in our experiments, data not
shown). By using accutase, problems with inhomogeneous cell
suspension were avoided, as were membrane damages resulting
from the detachment process. As depicted in Fig. 2c, as much
as 90% of the untreated cell population displayed low annexin V
and PI ﬂuorescence after detachment using accutase, indicating
that the experimental technique resulted in a low level of falsely
ﬂuorescing cells.
From these latter experiments, it is seen that the cells’ response
to HAL-PDT consisted of two dose regions, below and above
3.5 J cm-2, where doses higher than the threshold gave an
increased treatment response. Doses higher than 15 J cm-2 did
not further increase cell destruction. By using the lower irradiance
in the studies of apoptosis and necrosis, a larger accuracy in the
measurements was achieved. Still, in the areas of rapid decrease
in the survival curve (region around 300 s of light exposure),
the experimental error is larger than in other areas where the
response toHAL-PDT is slower. Thismay inﬂuence the parameter
estimation used with the single hit, multi target equation, and
could be the reason why the estimated values of n and D0 have
such large conﬁdence intervals.
The number of hits needed for inactivation of a cell was
estimated in a straight forward calculation to be to n = 10. This
value might seem high but it is in accordance with values obtained
by Juzeniene et al.,25 who found a value of n = 11 for ALA-
PDT (0.5 mM, 22 h, 420 nm, 10 ± 0.5 mW cm-2) performed on
WiDr cells. However, the detailed PDT mechanisms might well
be different in different cell lines and under all circumstances the
ﬁtting of a survival curve is strongly dependent on the weight
ascribed to the data points.
The results must therefore be regarded as indicative and only
pointing at a multi-target process during ALA based PDT.
Modes of cell death
The ﬂow cytometry results using the annexin V/PI assay indicate
that necrosis is the most important mode of cell death following
our HAL-PDT protocol. The outcome of photodynamic therapy
on cells does, however, depend on experimental factors,26 such
as photosensitizer concentration, and on internal factors, such
as cellular metabolic state.8 It also differs markedly between cell
lines. For example, Noodt et al.27 found that V79 Chinese hamster
ﬁbroblasts went into apoptosis after PDT while WiDr cells were
killed via necrosis. It is therefore difﬁcult to compare the amount of
apoptosis and necrosis after treatment between different cell lines.
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Fig. 5 Viable fraction (1 h and 24 h) after red light (630 nm, 20 mW cm-2, 5.4 J cm-2) HAL-PDT (10 mM, 3.5 h) measured by ﬂow cytometry with
annexin V/PI assay. MTT assay measurements (1 h and 24 h) after the same treatment are also shown (a). Apoptotic and necrotic fraction (1 h and 24 h)
after red light HAL-PDT, measured by ﬂow cytometry with annexin V/PI assay. The bars represent mean values ± SD of 3 independent and identical
experiments, each done in duplicates.
As PpIX is usually assumed to be formed in the mitochondria of
eukaryotic cells,28 it seems reasonable that HAL-PDT could lead
to mitochondria-mediated apoptosis.29–30 This was, however, not
reﬂected in the present experiments. One reason could be diffusion
of the produced PpIX to other intracellular membrane sites such
as lysosomes or the plasma membrane. Fluorescence microscopy
studies of AY-27 cells incubated with HAL (1 mM) for 3 h and 4 h
showed an accumulation of the lipophilic photosensitizer PpIX in
the plasma membrane.31 In our experiments an incubation time of
3.5 hwas used, which could accordingly lead to a sensitized plasma
membrane. Sufﬁcient oxidative damage tomolecules in the plasma
membranewill induce necrosis by loss of themembrane integrity.32
Also, the apparent increase in cell size at low doses, as indicated
by the increased forward scattering in ﬂow cytometry experiments
(Fig. 5), points at necrosis as the dominant path after HAL-PDT
under our conditions.
Experimental techniques may lead to hasty conclusions though.
The results presented in Fig. 5 clearly indicate some uncertainties
in the measurements of apoptotic levels. There is a discrepancy
between the apoptotic level and the mitochondrial activity mea-
sured 1 h and 24 h after treatment. In Fig. 5a, between 1 h and
24 h after treatment, the mitochondrial activity is dramatically
reduced. According to Plaetzer et al.33 the temporal dynamics
of the mitochondrial activity reﬂects the apoptotic fraction of
cells after AlPcS4-PDT on A431 cells when measured 3 and 24 h
after treatment. If we assume this to hold also in our case, a
large fraction of the cell population was apoptotic 1 h after
treatment andhad enterednecrosis 24 h after treatment. Inspecting
Fig. 5b, we also see that the necrotic fraction as measured by ﬂow
cytometry is strongly increased (25%) between 1 and 24 h. Still, the
increase in the necrotic fraction is not reﬂected in a decrease of the
apoptotic fraction, which would be expected as cells progress from
early to late apoptosis. These observations indicate that the ﬂow
cytometry method may have underestimated the level of apoptosis
after treatment, and that more robust methods should be used to
further investigate the modes of cell death after HAL-PDT. The
measurement point of 1 h after treatment was chosen to avoid
confusing late apoptotic cells with necrotic cells, assuming late
apoptosis does not occur within 1 h of HAL-PDT, while necrosis
does. The latter seemed to be justiﬁed as 50% of the cell population
was classiﬁed as necrotic 1 h after incubation with HAL and
illumination equivalent to 5.4 J cm-2. Still, estimates of the time
from cell damage to death by necrosis vary, and according to
Kramer et al.34 necrosis may not occur before 2–4 h after the
triggering injury.
The effects of fractionated radiation
We found no difference in PDT efﬁcacy between fractionated
and continuous light delivery. The surviving fractions measured
by MTT and ﬂow cytometry after identical PDT protocols
were different, the MTT always providing a lower estimate of
cell survival. However, since the two techniques use different
mechanisms to measure cell viability, the difference in cell survival
between the two light regimes is more important than the exact
values of cell survival measured by a single technique.
The usefulness of fractionated exposure is debated in the
literature. The different light protocols used, the different cell
types tested etc., provide reasons for discrepancies. It has been
reported that fractionation is not successful in clinical ALA-PDT
of hamster melanoma.35 On the other hand, Curnow et al.36–37
reported more necrosis when light treatment was interrupted by a
single dark period in rat colon cells. De Bruijn et al.38 also report
improvement of nodular tumor response when interrupting light
delivery with a substantial dark period.
The treatment regime used in the present experiments consisted
of light/dark/light intervals of 45 s/60 s/45 s until the LD50 (1 h,
ﬂow cytometry) dose of 5.4 J cm-2 was reached and the procedure
was adapted from Oberdanner et al..39 They reported a decrease
in the PDT efﬁcacy with this light regime, using the lipophilic
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photosensitizer hypericin on the adherent A431 cell line. Their
experimental conditions resemble those in our system, where the
lipophilic photosensitizer PpIX is used in photodynamic therapy
of the adherent AY-27 cell line. Oberdanner et al. suggested
that fractionated photodynamic therapy in vitro is inﬂuenced
by recycling of the ROS quenching GSH (reduced glutathione)
by glutathione reductase during the dark intervals, which could
explain the increase in survival levels when fractionated irradiation
was used. Although we did not see a similar difference between
the different modes of light delivery, it would be of interest to
test for possible effect on survival rate from addition of BCNU,
an inhibitor of glutathione reductase, to the cultivation medium
before irradiation. Decreased survival would then support a
participation of the GSH system.
Conclusion
The present data on AY-27 cells facilitate the choice of HAL-
PDT parameters to be chosen on further study and treatment of
bladder cancer. HAL-PDT seems to be as efﬁcient in the blue
as in the red light regime (dose properly adjusted) as expected
since protoporphyrin IX acts as the photosensitizer. It should,
therefore, be possible to optimize the PDT protocol with respect
to tissue penetration of different wavelengths. Our survival curves
indicate practical doses for HAL-PDT and the experiments with
fractionated exposure do not indicate further efﬁcacy of HAL-
PDT by this technique. We could not ﬁnd apoptosis to be a
dominant pathway to cell destruction, but this could be inﬂuenced
by our experimental techniques. As apoptosis may be desirable
fromclinical point of view, the optimum treatment deserves further
studies.
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Abstract. Hexyl 5-aminolevulinate (HAL) is a lipophilic derivative of 5-aminolevulinate, a key intermediate in
biosynthesis of the photosensitizer protoporphyrin IX (PpIX). The photodynamic efficacy and cell death
mode after red versus blue light illumination of HAL-induced PpIX have been examined and compared
using five different cancer cell lines. LED arrays emitting at 410 and 624 nm served as homogenous and adjust-
able light sources. Our results show that the response after HAL-PDT is cell line specific, both regarding the
shape of the dose-survival curve, the overall dose required for efficient cell killing, and the relative amount of
apoptosis. The ratio between 410 and 624 nm in absorption coefficient correlates well with the difference in cell
killing at the same wavelengths. In general, the PDT efficacy was several folds higher for blue light as compared
with red light, as expected. However, HAL-PDT624 induced more apoptosis than HAL-PDT410 and illumination
with low irradiance resulted in more apoptosis than high irradiance at the same lethal dose. This indicates
differences in death modes after low and high irradiance after similar total light doses. From a treatment per-
spective, these differences may be important. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported
License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1
.JBO.19.8.088002]
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1 Introduction
Presently, 5-aminolevulinate (ALA) and two of its derivatives
[methyl 5-aminolevulinate and hexyl 5-aminolevulinate
(HAL)] are in routine clinical use as photosensitizer precursors
in photodynamic therapy (PDT) and photodiagnosis.1,2 HAL
shows improved tissue penetration3–5 and cellular uptake6–8
compared to ALA. Following conversion of HAL to ALA by
cellular esterases, the molecule enters the heme synthesis
pathway and induces increased intracellular levels of the photo-
sensitizer protoporphyrin IX (PpIX), the direct precursor of
heme. PpIX features a typical absorption spectrum for porphyr-
ins with a high Soret peak around 410 nm and Q-bands in the
green and red wavelength ranges.9 For PDT or photodiagnosis
based on ALA or its esters, both blue and red light lamps are
used. Red light offers the advantage of deeper penetration into
tissue (about 6 mm).2,10–12 By contrast, blue light penetrates only
about 1 mm into tissue,13 but has much higher efficiency for
PpIX activation.
Protocols for PDT treatment in research and in the clinic
vary widely, probably at least in part because there is no strong
scientific basis for choosing one protocol over another. A sol-
ution to this problem will require comparative analyses of
biological effects of different photophysical parameters, such
as light wavelength, irradiance, and total dose. In addition,
general conclusions can only be made by analyzing the effects
of the same protocol applied to different tissues and cancer
cells.
While treatment by chemotherapy and radiation largely kill
cells by apoptosis, apparently PDT may work through apopto-
sis, necrosis, autophagy, and even mitotic catastrophe.2,14–18
In general, the death mode may depend on several factors,
including cell-specific properties, type of photosensitizer, light
wavelength, total light dose, and irradiance.17,19–21 Interestingly,
the irradiance also modulates immunological responses which
are likely to affect treatment outcome. Thus, high irradiance
was found to be immunosuppressive, whereas a similar total
dose administered using lower irradiance was not immuno-
suppressive.22 In the present study, we have used five different
human cancer cell lines and compared the overall PDT effi-
ciency when using HAL-induced PpIX as photosensitizer acti-
vated by light of either 410 or 624 nm. We observed substantial
differences among the cell types in their sensitivities to light.
More importantly, the death mode, here measured as apoptosis,
was not only influenced by the light source and total light
dose but also by irradiance. From a perspective of treatment
efficacy, our results may contribute to a better fundament for
understanding the biological effects of the photophysical param-
eters in PDT.
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2 Materials and Methods
2.1 Cell Lines
Five human cancer cell lines were used in this study, all of them
representative of a cancer type suitable for clinical HAL-PDT.
The cell line A431 (ATCC CRL‐1555) is an epidermoid carci-
noma and serves as a model system for skin cancer. The A549
cell line (ATCC CCL-185) is a lung carcinoma and HeLa S3
(ATCC CCL-2.2) is a cervical adenocarcinoma. WiDr (ATCC
CCL-218) is a colorectal adenocarcinoma and T24 (ATCC
HTB-4) is a transitional cell carcinoma from urinary bladder.
2.2 Light Sources
To obtain a homogenous light field at appropriate wavelengths
and within a range of irradiance values, light sources based on a
light emitting diode (LED) array were used for this study.23 Each
lamp consists of an array containing 247 (13 × 19 diodes,
624 nm, illumination field 9 × 14 cm) or 260 (13 × 20 diodes,
410 nm, illumination field 9 × 15 cm) LEDs (Roithner
LaserTechnik, Vienna, Austria) connected in parallel. The irra-
diance of these LEDs is adjusted by the current applied as
described by Pieslinger et al.23 The assembly of the LEDs
and the distance from the LEDs to the illumination field are opti-
mized to achieve a homogenous light field (maximal variation
10%). The LED light source for blue light illumination (LED
type VL410-5-15, dominant wavelength 410 nm, spectral
half-wave width 18 nm) allows for irradiance values up to
7.0 mW∕cm2, and the red light illumination source (LED
type R5CA5111P, dominant wavelength 624 nm, spectral
half-wave width 20 nm) delivers up to 35.0 mW∕cm2. The emit-
tance spectra can be found in Ref. 24 and the light viewing angle
is 15 deg. Irradiance was measured in a grid pattern (covering
the whole light field) by an LI-189 light meter equipped with a
PY pyranometer detector (LI-COR, Lincoln, Nebraska, diam-
eter 7.5 mm) and a LabMaster Ultima laser measurement system
with a vis-sensor (Coherent Inc., Wilsonville, California, diam-
eter 8 mm). Both light meters had a typical accuracy of 3%
for the total system. The light transmission of the microplates
used is reported to be close to 100% at wavelengths >350 nm
according to information from the manufacturer. The transmis-
sion spectrum should, therefore, be close to that of the lamp
itself.
2.3 Cell Culture
All growthmediawere supplementedwith 10% (v/v) fetal bovine
serum, 2 mM L-glutamine, 100 Uml−1 penicillin∕0.1 mgml−1
streptomycin, amphothericin B (2.5 μg∕ml), and 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), all
obtained from Sigma (Oslo, Norway). For culture of T24
and A431, 1-mM Na pyruvate (BioWhittaker, Lonza, Belgium)
was also added to the media. All cell lines used Dulbecco's
modified eagle medium (DMEM) as a basic medium except
for WiDr cells which were cultured in RPMI 1640 medium.
Subcultivation was done by rinsing the cells twice with phos-
phate buffered saline (PBS) (37°C) before detachment by tryp-
sinization. For all experiments, cells were seeded in appropriate
cell culture dishes the day before treatment. Cell numbers
(total, live, and dead) were determined by using the Countess™
system (Invitrogen™, Oslo, Norway) and the number of live
cells was used for calculating the seeding.
2.4 Hexyl 5-Aminolevulinate Photodynamic Therapy
A stock solution of 10 mM HAL dissolved in PBS (adjusted to
pH 6.0) was freshly prepared on the day of the experiment and
sterilized by filtration (0.2-μm filter). The growth medium was
carefully removed from the dishes and replaced by medium
without serum containing 20 μM HAL. After 3 h of incubation
(dark conditions, 37°C, 5% CO2, humidified atmosphere), the
HAL medium was replaced by growth medium without HAL
(with serum). The samples were illuminated from below using
either of the LED arrays described above immediately after
HAL removal and were subsequently placed in the incubator
until further processing. All experimental steps after adding
of HAL to the cells were done under subdued light conditions.
2.5 Dose-Response
Cells were seeded (1 day before treatment) in 96-well cell cul-
ture microplates (black walls, clear bottom, Optilux, Falcon,
VWR, Norway, see picture in Fig. 1) at the following densities,
resulting in 50% to 60% confluency at the day of treatment:
A431: 10,000 cells/well, A549: 10,000 cells/well, HeLa S3:
11,000 cells/well, T24: 9000 cells/well and WiDr: 11,000
cells/well. The standard filling volume was 100 μl∕well. Six
wells in each row contained cells while the outer ones only con-
tained medium to minimize evaporation. Every experiment was
accompanied by a “control” [no Photosensitizer (PS), no light],
a “light-only” sample (no PS, maximal light dose), and a “HAL-
only” sample (PS, kept in the dark). Please notice that all doses
and controls necessary for the one dose–response curve were on
the same microplate to ensure identical conditions except those
of the varied photophysical parameters.
2.6 Resazurin Assay
The resazurin assay is based on the conversion of the non-
fluorescent resazurin to the fluorescing resorufin in viable
cells. Approximately 22 h after illumination, 20-μl resazurin
(2.5 mM, Sigma) was added into each well and incubated for
3 hours
Cells + 20 μM HAL
Cells with endogenously 
produced PpIX PpIX spectrometry
Photophysical parameters:
624 nm (35 mW/cm2)
410 nm (0.7, 3.5 and 7.0 mW/cm2)
Total cell death 
(resazurin assay)
Caspase 3/7 activity
0, 2, 5 and 8 hours24 hours
0 hours
A431 and T24 cell line
A431 and T24 cell line, 
triplicate, 3 experimentsAll 5 cell lines, 
sextuplicates, 
3 - 5 experiments
Fig. 1 A flow chart of the experimental design including the number of
parallels and experiments is presented.
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2 h in the dark incubator. Subsequently, resorufin fluorescence
was determined using a microplate reader (BMG Labtech
FluoStar Omega, Oslo, Norway, excitation wavelength 544 nm,
emission wavelength 590 nm).
2.7 PpIX Absorbance and Emission
Approximately 95% confluent 75 cm2 cell culture bottles of
T24 and A431 cells were incubated with 20 μM HAL for
3 h. Cells were then rinsed once with PBS (37°C) and 5 ml
of accutase (Sigma) was added. After a few minutes in the
incubator, the detached cells were transferred into tubes.
From each cell suspension, 10 μl were taken for cell counting
by Bürker chamber. The suspensions were then centrifuged at
450 g (4°C, 5 min). The supernatants were removed and the
pellets were resuspended in PBS to a final concentration of
4.0 × 106 cells∕ml. All samples were kept on ice until spectra
were read using a Fluorolog III fluorometer (Jobin Yvon-Spex,
Horiba Group, Kjeller, Norway). For the fluorescence-excitation
spectra, an LP700 filter was placed in front of the detector, the
excitation slit was 3 nm, and the emission slit was 4 nm.
Fluorescence emission was measured at 710 nm and excitation
was performed in 1-nm steps from 350 to 700 nm in a signal/
reference mode to make it comparable to absorption spectra.
Emission spectra (550 to 750 nm, 1-nm step width) were excited
at 405 nm with an excitation slit at 4 nm and an emission slit
at 3 nm.
2.8 Caspase 3/7 Activity
The lethal dose (LD) values as determined from the dose–
response curves for A431 and T24 cells in Figs. 2 and 3
were used for this part of the study. For determination of the
caspase activity, cells were seeded the day before treatment in
Optilux-microplates (cell density: 9000/well for T24 10,000/
well for A431). HAL-PDT was done as described above, but
the cells were covered with only 30 μl medium (with serum)
per well after illumination. At 0, 2, 5, and 8 h post illumination,
a microplate was allowed to equilibrate to room temperature
before 30 μl of Caspase-Glo® 3/7 Reagent (Promega, Oslo,
Norway, room temperature, in accordance with the manufac-
turers’ protocol) was added to each well. The samples were
mixed on a plate-shaker at 500 rpm for about 30 s and were
subsequently incubated at room temperature for 1 h before
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0.05 0.10 0.15 0.20 0.25 0.30
0
20
40
60
80
100
light dose (J/cm2)
re
l.s
ur
vi
va
l (
% 
un
tre
ate
d c
on
tro
l)
A549
0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
20
40
60
80
100
light dose (J/cm2)
re
l.s
ur
vi
va
l (
% 
un
tre
ate
d c
on
tro
l)
HeLa S3
0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
20
40
60
80
100
light dose (J/cm2)
re
l.s
ur
vi
va
l (
% 
un
tre
ate
d c
on
tro
l) T24
0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
20
40
60
80
100
light dose (J/cm2)
re
l.s
ur
vi
va
l (
% 
un
tre
ate
d c
on
tro
l)
WiDr
0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
20
40
60
80
100
0.7 mW/cm2
3.5 mW/cm2
7.0 mW/cm2
light only - 0.7 mW/cm2
light only - 3.5 mW/cm2
light only - 7.0 mW/cm2
light dose (J/cm2)
re
l.s
ur
vi
va
l (
% 
un
tre
ate
d c
on
tro
l)
Fig. 2 Dose–response curves for five human cancer cell lines treated with blue light (410 nm) HAL-PDT
(20 μM, 3 h, serum free). Three different irradiance values (0.7, 3.5 and 7.0 mW∕cm2) were used for all
cell lines. Cell viability is relative to an untreated control in the same microplate (no HAL, no light) and the
0 J∕cm2 point is the “HAL no light” value. Each point is the average of two to five experiments (each in
sextuplicate) with standard error of the mean (SEM) indicated by error bars.
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luminescence was measured in the plate reader (BMG Labtech
FluoStar Omega).
2.9 Calculations and Statistics
All calculations for LD values are based on Figs. 2 and 3. The
LD’s are simply read out, such as LD25 equals the dose needed
to obtain 25% cell death, LD50 equals the dose needed to obtain
50% cell death and so on. Unfortunately, the exact same doses
were not used for all experiments. This made it difficult to make
a statistical comparison between the curves in Figs. 2 and 3.
The reason that doses were sometimes slightly altered between
the independent experiments was to improve the measurement
points in order to show the expected sigmoidal shape of the
curve. Normally one expects an experimental error of 10% to
15% in MTT and resazurin assays. For calculating the mean
and standard error of the means (SEMs) in Figs. 2 and 3, the
values from sextuplicate measurements in all three to five bio-
logical replicates were added together and used to calculate
mean values and SEMs.
3 Results
3.1 Dose–Response Curves of Five Human Cancer
Cell Lines after Blue Light HAL-PDT
To address the question of whether the cytotoxicity of blue light
illumination of HAL-induced PpIX (abbreviated as HAL-
PDT410 is dependent only on total light dose or on total light
dose and irradiance, we measured dose–response curves of five
human cancer cell lines using three different irradiance values (0.7,
3.5 or 7.0 mW∕cm2) under otherwise identical PDT procedures.
As shown in Fig. 2, the overall light dose required to kill
close to 100% of the cells varies from 0.2 to 1.4 J∕cm2, depend-
ing on the cell line. The most sensitive cell line is A431 both in
terms of the irradiance and light dose required for complete
cell killing, whereas the other cell lines are substantially
more resistant. The shape of the dose–response curves differs
among the different cell lines. The viability of T24 cells drops
rapidly with increasing light dose, while the dose–response
curve for HeLa S3 cells has a slight slope (depending on the
irradiance) with a near complete cell kill at >1.1 J∕cm2.
WiDr displays a notable similarity to T24 cells regarding
curve characteristics, excluding the HAL-only measurement.
Unexpectedly, a less steep dose–response curve was observed
when using a lower irradiance (0.7 mW∕cm2) compared to a
10-fold higher irradiance (7 mW∕cm2). This was observed for
all five cell lines.
The dark toxicity of 20-μM HAL varied from 35% (A549)
to negligible (A431, T24). Blue light illumination without PS
using the maximal light dose resulted in up to 40% cell
death for A549 cells, and almost no cell killing for A431
and WiDr cells. Hyperthermia from illumination could poten-
tially cause some of the differences between high and low irra-
diance. However, the temperature in growth medium did not
change measurably for 410 nm (7 mW∕cm2, 30 min) illumina-
tion and increased only 2 deg for 624 nm (35 mW∕cm2,
30 min), data not shown. Since illumination is carried out at
room temperature, the cells will consequently not be exposed
to hyperthermia during the PDT protocols employed.
3.2 Dose–Response Curves of Five Human Cancer
Cell Lines after Red Light HAL-PDT
Red light is commonly used for ALA-based PDT in the clinic.
As a result of PpIX’s low absorption of red light compared
to blue light and the irradiance range of the lamp, only the
highest lamp output irradiance (35 mW∕cm2) was used for
red light HAL-PDT (HAL-PDT624). An exception is the
A431 cells which required the lowest light doses. Therefore it
was possible to establish a dose–response curve for 7 mW∕cm2
illumination as well. For an irradiance of 35 mW∕cm2, the
illumination time required to achieve near complete cell destruc-
tion was below 30 min for all cell lines tested. Except for irra-
diance and wavelength, the PDT parameters were identical
to those in the HAL-PDT410 experiments. Dose–response
curves for all five cell lines after HAL-PDT624 are presented
in Fig. 3(a).
Similar to the dose–response curves for HAL-PDT410,
the dose–response curves of the individual cell lines to
HAL-PDT624 differ in both shape and the light doses needed
to achieve close to 100% cell killing. The required light
doses for near complete cell kill varied from 12.6 J∕cm2 for
A431 to >70 J∕cm2 for WiDr and A549. Interestingly, the
order of sensitivity of the cell lines to PDT estimated from
LD∼100 values (A431 > HeLa S3 > T24 >WiDr > A549) is
comparable for HAL-PDT410 and HAL-PDT624. Furthermore,
A549 cells showed a biphasic response to HAL-PDT624 (and
not a biphasic response to HAL-PDT410): a rapid drop in viabil-
ity below 10 J∕cm2 is followed by a plateau up to 40 J∕cm2.
At an even higher light dose (70 J∕cm2), the viability of
A549 cells drops to nearly zero. For the cell line with highest
sensitivity to HAL-PDT624, A431, the influence of irradiance on
the overall cytotoxicity was tested. The results from this experi-
ment are presented again in Fig. 3(b), where lower irradiance
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Fig. 3 Dose–response curves for five human cancer cell lines treated
with red light (624 nm) HAL-PDT (20 μM, 3 h). In (a) all five cell lines
were illuminated at 35 mW∕cm2 and in (b) A431 cells were illuminated
with 7 mW∕cm2 in addition (n ¼ 6, small SEMs on error bars). Cell
viability is relative to an untreated control in the same microplate
(no HAL, no light) and the 0 J∕cm2 point is the “HAL no light”
value. Each point in (a) is the average of two to five experiments
(each in sextuplicate) with standard error of the mean (SEM) indicated
by error bars.
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(7 mW∕cm2) results in less efficient cell destruction for inter-
mediate doses when compared to the fivefold higher irradiance
(35 mW∕cm2).
As expected, the dark toxicity of 20 μM HAL in these
experiments was about the same as in the HAL-PDT410 experi-
ments. Furthermore, red light illumination without PS using the
maximal light dose for each cell line induced no cell death
within the experimental error, except for A549, which showed
about a 30% drop in viability.
To make comparison between the different cell lines and
photophysical parameters easier, we have assembled the values
from Figs. 2 and 3 in Table 1. We have tabulated the values
resulting in 25%, 50%, 75%, and 90% cell death, for LD25,
LD50, LD75, and LD90, respectively. Since the slope of the
dose–response curves is very flat when approaching 100%
cell death, the definition of LD100 is somewhat subjective, and
we chose to use the term “LD∼100” instead. At LD∼100, close to
100% of the cells were dead in all experiments when measured
by resazurin assay and there were no signs of viability on visual
inspection of the cells.
3.3 Spectra of Intracellular HAL-Induced PpIX
In order to identify PpIX and possible its derivatives by spec-
troscopy, fluorescence excitation [Fig. 4(a)] and emission spec-
tra [Fig. 4(b)] of HAL-induced intracellular PS were recorded in
A431 and T24 cells.
A431 and T24 were chosen as models for a PDT sensitive
and a more resistant cell line, respectively. A431 is the most
sensitive to HAL-PDT of all tested cell lines for both blue
and red light illumination, while T24 is one of the most resistant
cell lines when one compares doses required to achieve close to
Table 1 Calculated LD values based on Fig. 2 and Fig. 3, LD values are given in J∕cm2. In the upper part of the table, LD values for HAL-PDT410
are presented and the corresponding LD-values for HAL-PDT624 are presented in the lower part of the table. For a few measurements, the dark
toxicity was too high to make a LD25-calculation, the missing values are denoted “–”.
HAL-PDT410 A431 A549 HeLa S3 T24 WiDr
½mW∕cm2 0.7 3.5 7.0 0.7 3.5 7.0 0.7 3.5 7.0 0.7 3.5 7.0 0.7 3.5 7.0
LD25 0.04 0.03 0.03 – – – 0.07 0.02 0.03 0.02 0.02 0.02 – – –
LD50 0.07 0.06 0.06 0.25 0.19 0.14 0.34 0.22 0.15 0.06 0.06 0.06 0.08 0.09 0.07
LD75 0.09 0.08 0.07 0.69 0.36 0.41 0.58 0.39 0.26 0.13 0.13 0.11 0.36 0.26 0.20
LD90 0.12 0.10 0.09 1.05 0.64 0.62 0.77 0.56 0.48 0.35 0.20 0.19 0.96 0.62 0.52
LD∼100 0.25 0.25 0.25 1.40 1.40 1.40 1.10 1.10 1.10 1.20 1.20 1.20 1.40 1.40 1.40
HAL-PDT624 A431 A549 HeLa S3 T24 WiDr
½mW∕cm2 7 35 35 35 35 35
LD25 5.7 3.4 – 4.4 1.7 –
LD50 7.7 5.1 28.9 26.3 3.8 4.5
LD75 9.6 6.9 63.0 56.3 7.5 28.4
LD90 11.7 8.3 72.1 66.0 13.8 69.2
LD∼100 12.6 12.6 – 69.3 69.3 70.0
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Fig. 4 Spectra of intracellular HAL-induced (20 μM, 3 h) PpIX
and possible derivatives thereof in A431 and T24 cells
(4 × 106 cells∕ml). The spectra from untreated cells are subtracted
from the presented PpIX spectra. (a) Fluorescence at 710 nm was
measured for excitation wavelengths from 350 to 700 nm at 1 nm
steps in signal/reference mode, making the spectra equivalent to
absorption spectra. (b) Cells were excited at 410 nm and emission
measured at 1 nm steps from 550 to 750 nm.
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100% cell killing. Both fluorescence excitation and emission
spectra of untreated cells were measured (negligible values)
and subtracted from the spectra measured from the incubated
cells [Figs. 4(a) and 4(b)]. For both cell lines, the Soret
peak is clearly visible at 410 nm and the maximum of the
Q-band in the red wavelength range is close to 633 nm
under the conditions used [Fig. 4(a)]. The ratio of the fluores-
cence excitation peaks (equivalent to absorption peaks) at 410
and 633 nm between the two cell lines A431 and T24 is 0.6
(T24:A431).
At 624 nm, the red light fluorescence excitation peak has
dropped to 55% from its maximum at 633 nm. Therefore,
the overall illumination period could be reduced by roughly
one half if a light source with a maximum at 633 nm was
used for illumination instead of the 624 nm as used in the
present experiments.
The ratio between the peak heights of 410 and 624 nm is 56.3
for A431 and 56.4 for T24 cells, under the conditions used in
this study [Fig. 4(a)].
T24 cells had lower fluorescence emission than A431 cells
[Fig. 4(b)]. Red light fluorescence emission peaks at 636 nm
for both cell lines, while a smaller maximum was determined
at 706 nm. For both peaks, the overall fluorescence from T24
cells is about half of the fluorescence value from A431 cells.
3.4 Caspase 3/7 Activity in A431 and T24 Cells
Induced by HAL-PDT410 and HAL-PDT624
To test whether different illumination parameters influence
apoptosis induction in A431 and T24 cells, caspase 3/7 activity
was measured at 2, 5 and 8 h post HAL-PDT. These time points
were chosen according to the results of a pilot study. Caspase 3/7
activity is considered a hallmark of apoptosis. Both cell lines
were selected due to their property to show the full apoptotic
phenotype, clear caspase induction, and comparable susceptibil-
ity toward HAL-PDT [see Figs. 2 and 3(a)]. A431 and T24 cells
were again used to represent sensitive and more resistant cell
lines to HAL-PDT, respectively. All LD values in this study
are based on interpolated data from Figs. 2 and 3, therefore, bio-
logical and technical variations in these experiments are carried
on into the LD values. In addition, the caspase measurements
were first done based on the LD values from one dose-response
experiment. The light doses were kept fixed in all three indepen-
dent experiments, but it turned out after all dose-response
experiments were done for Figs. 2 and 3 that the light doses
used to obtain the bars in Figs. 5 and 6 did not result in identical
LD values for all different photophysical parameters. As a result,
the doses are assembled in subranges in Figs. 5 and 6. All values
shown in Figs. 5 and 6 are relative to an untreated control (no
light, no PS) set as 100%.
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Fig. 5 Caspase 3/7 activity of A431 and T24 cells following HAL-PDT with 410-nm light and
(a) 0.7 mW∕cm2 and (b) 7.0 mW∕cm2. Values are related to an untreated control, set as 100%.
Caspase 3/7 activity was measured for different light doses at 2, 5, and 8 h after completed illumination.
Bars represent averages from three independent experiments with triplicates in each experiment and
SEMs are indicated.
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3.4.1 HAL-PDT410
In order to determine the effect of varying irradiance,
HAL-PDT410 was performed using irradiance values of either
0.7 mW∕cm2 [Fig. 5(a)] or 7.0 mW∕cm2 [Fig. 5(b)]. In
Fig. 5(a), a low dose corresponds to about LD35, a sub-low
to LD65, a sub-full to LD85, and a full dose close to 100%
cell death. In Fig. 5(b), the variance in the dose ranges is some-
what larger: the low dose corresponds to about LD20 (A431) and
LD30 (T24), the sub-low to LD35 (A431) and LD60 (T24), the
sub-full to LD85, and the full dose close to 100% cell death.
Among the light doses tested, sub-full doses generally
induced the highest caspase 3/7 activity in A431 cells at all
three time points for both irradiance values. The results are
similar for T24 cells but the less pronounced and for the lowest
irradiance for the sub-low doses seem to induce the highest
caspase 3/7 activity. Furthermore, caspase 3/7 activity increases
with increasing time post HAL-PDT in the time range tested.
A431 generally shows higher caspase 3/7 activity when com-
pared to T24.
3.4.2 HAL-PDT624
In Fig. 6, a low dose corresponds to about LD20 (A431) and
LD30 (T24), a sub-low to LD40 (A431) and LD50 (T24), a
sub-full to LD65 (A431) and LD75 (T24), and a full dose
close to 100% cell death. Following red light illumination,
T24 cells show almost no increased caspase 3/7 activity for
any of the light doses and time points tested in this study
(Fig. 6). Only a marginal increase was observed at 5 and 8 h
for sub-low and sub-full doses. By contrast, A431 displayed
increasing caspase 3/7 activity with increasing light doses at
5 and 8 h post HAL-PDT624.
Interestingly,when comparingHAL-PDT410 toHAL-PDT624,
the most pronounced differences of caspase 3/7 activity are
that (i) blue light induces the highest activity at sub-full doses
(except for T24 0.7 mW∕cm2) but red light does so at full
doses (except forT24which showedonlyminor caspase3/7 activ-
ity after HAL-PDT624) and (ii) blue light induces a maximum
threefold increase in the activity when compared to untreated
controls while red light induces a maximum fourfold increase.
4 Discussion
Although the basic principle of PDT is simple, a number of
physical, chemical and biological parameters may influence its
efficacy. Different light sources with diverse characteristics are
used both in research and in clinical applications.25,26 By alter-
ing the illumination period, different irradiance values can be
used to deposit one specific light dose. However, the tumor
response may not solely depend on the light dose but may
also depend on the irradiance. In clinical application, lower
irradiances turned out to be more effective than higher
ones (above a specific threshold) due to a limitation of the
(tissue) oxygen supply.27–30 This effect is assumed not to
be the case for in vitro experiments, where the oxygen supply
is much better than in tissues. In HAL-PDT, the effective pho-
tosensitizer is endogenous PpIX, which has its largest absorp-
tion around 410 nm and a smaller peak of absorption around
630 nm. Red light is commonly used in PDT due to its longer
penetration depth in tissue. In the present study, all cells were
monolayer cells and were irradiated from below. Hence, scat-
tering, depth of penetration, and cell density would not make
a large impact on light delivery. The significance of these
parameters is, however, of great importance in clinical treat-
ment. In a study from 2011, the efficacies of different light
sources used in the clinic to activate PpIX were compared
and demonstrated that blue light sources were the most effi-
cient.31 Blue light was also used successfully in several der-
matological conditions.32–35
We have used two in-house made lamps to examine whether
there is a difference in the outcome of HAL-PDT with red and
blue light and after illumination with different irradiances in five
different human cancer cell lines. The following discussion is
divided into three main topics: irradiance and wavelength,
cell-line specific response, and apoptosis induction.
4.1 Irradiance and Wavelength
Interestingly, our cell survival studies indicate that when using
blue light and identical total light doses, high irradiance is more
efficient in cell killing than low irradiance. This tendency is
most strongly pronounced for A431 and HeLa S3 cells. In addi-
tion, at least for A431 cells, high irradiance red light induces a
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Fig. 6 Caspase 3/7 activity in A431 and T24 cells following HAL-PDT with 624 nm light at 35.0 mW∕cm2.
Values are related to an untreated control, set as 100%. Caspase 3/7 activity was measured for different
light doses at 2, 5, and 8 h after completed illumination. Bars represent averages from three independent
experiments with triplicates in each experiment and SEMs are indicated.
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higher cytotoxicity than low irradiance at an identical total light
dose. This observation may be (at least partially) ascribed to the
counteracting effect of the cellular reactive oxygen species
(ROS) defense systems, which have been shown to antagonize
PDTwhen fractionated illumination is applied.36 It seems likely
that during longer illumination at lower irradiance, the ROS
defense may have sufficient capacity to partially detoxify the
PDT-induced oxidants. By contrast, high-irradiance PDT
might overwhelm the antioxidative mechanisms.
The absorption ratios between 410 and 624 nm were ∼56 for
both cell lines, A431 and T24 [Fig. 4(a)]. This generally corre-
lates quite well with killing efficiencies (Table 1), although there
is some variation at different LD values. Wavelength-dependent
light absorption by PpIX is probably a major parameter in PDT,
but probably not the only one. Other factors likely to contribute
are ROS detoxification, such as superoxide dismutase, as well as
DNA repair and autophagy.
A difference in killing dependent on irradiance but with a
constant dose has also been studied when using another sensi-
tizer. Thus, a photofrin II PDT study on A549 cells demon-
strated lower efficacy at lower irradiance values.37 Although
a lower irradiance may reduce killing in PDT treatment, that
reduction might then to some extent be compensated by an
improved oxygenation.38
4.2 Cell-Line Specific Responses
Essentially, the response to PDT treatment differs notably
between cell lines, both regarding sensitivity and shape of sur-
vival curves (Figs. 2 and 3). Similar observations were made by
others using different cell lines and PDT protocols.39 Obviously,
generation of increased amounts of PpIX is essential for efficient
PDT. However, T24 has only half the amount of total PpIX
when compared to A431 (Fig. 4), but is more than twice less
sensitive to light (at least at wavelength 410 nm) than A431,
again pointing to a complex basis for sensitivity to PDT treat-
ment. Difference in the survival of different cell lines could
possibly be explained by different intracellular distributions of
PpIX. However, confocal microscopy of HAL-incubated cells
(20 μM, 3 h) co-stained with MitoTracker Green performed
in this study indicated that PpIX is mainly localized in mito-
chondria in all cell lines used here. After another hour of HAL-
incubation, some PpIX is redistributed to the cell membrane,
without notable differences between the cell lines (data not
shown). To explore the basis for the different sensitivities would
require substantial efforts beyond the scope of the present paper,
but it is likely that cell-specific differences in response of cancer
cell lines also apply to tumors.
4.3 Apoptosis Induction
Apoptosis and necrosis are two major modes of cell death. We
have specifically examined apoptosis and have assigned cell
death that was not clearly apoptotic to most likely be necrotic.
We consequently assume that the difference between the resa-
zurin results and the caspase 3/7 activity measurements is
caused by necrosis. However, there are additional mechanisms
of cell death, including mitotic catastrophe and autophagy, both
of which may, in fact, have a role in PDT.21,40 The cell death
mode apparently may depend both on the type of sensitizer
and properties of the cells being treated. Apoptosis and mitotic
catastrophe have some common and some unique proper-
ties.41,42 PDT was shown to trigger immune suppression at
high irradiances but immune stimulation at low irradiances in
normal skin.22 This is interesting from the perspective of differ-
ent death modes observed at high and low irradiance in
our study. Stimulation of antitumor immunity after PDT is
recognized, but the details/trigger mechanisms are still dis-
cussed.43–46 Exploration of the effect of different illumination
protocols on cell death mode in vitro may help in establishing
a better basis for the choice of illumination parameters.
To examine the influence of different illumination parameters
on the cell death mode, caspase 3/7 activity was measured at 2, 5
and 8 h post-illumination. These results demonstrate that the cel-
lular response depends on the target cells as well as illumination
protocol. The most pronounced difference in caspase 3/7 activ-
ity between blue and red light PDT was that HAL-PDT410
showed maximal caspase 3/7 activity at sub-full doses and
HAL-PDT624 maximum at full doses, which appears to be
quite unique. For comparison, an ALA-PDT study on five differ-
ent cell lines showed that the time course of apoptosis varied
between the different cell lines and that the amount of apoptosis
and necrosis varied with the cell line and dose, which is in line
with the results presented in our study.47
In conclusion, the shape of the dose survival curve, the LD
values, and the amount of apoptotic cells vary significantly
between the different cell lines examined. When comparing
blue and red light illumination, the light absorbance of the
respective wavelength corresponds well to the light sensitivity
of the cells. Furthermore, there has been some uncertainty as
to whether one could make a direct comparison or not between
studies when different wavelengths or irradiances have been
used. This study shows that if one compares results between
studies with either different irradiances or wavelengths, one
should be especially aware of the differences at sublethal doses.
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Photodynamic therapy (PDT) using blue light and the potent precursor for protoporphyrin IX, hexyl
aminolevulinate (HAL), has been shown to induce apoptosis and necrosis in cancer cells, but the
mechanism remains obscure. In the present study, we examined protein carbonylation, expression levels
and post-translational modiﬁcations in rat bladder cells (AY-27) after PDT with HAL. Altered levels of
expression and/or post-translational modiﬁcations induced by PDT were observed for numerous
proteins, including proteins required for cell mobility, energy supply, cell survival and cell death
pathways, by using two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry
(MS). Moreover, 10 carbonylated proteins associated with cytoskeleton, transport, oxidative stress
response, protein biosynthesis and stability, and DNA repair were identiﬁed using immunoprecipitation,
two-dimensional gel electrophoresis and MS. Overall, the results indicate that HAL-mediated PDT
triggers a complex cellular response involving several biological pathways. Our ﬁndings may account
for the elucidation of mechanisms modulated by PDT, paving the way to improve clinic PDT-efﬁcacy.
1. Introduction
5-Aminolevulinic acid (ALA) is an endogenous precursor for pro-
toporphyrin IX (PpIX) formed via the heme biosynthetic pathway.
It has been shown that certain tumor cells have a large capacity
to synthesize the photosensitizer PpIX in mitochondria when
exposed to adequate concentrations of exogenous ALA because
of low activity of ferrochelatase and elevated porphobilinogen
deaminase.1 Hexyl aminolevulinate (HAL) is an ester of ALA
that is effectively converted into free ALA by esterases in cytosol
before entering into the heme biosynthetic pathway.2,3 The uptake
mechanisms of ALA and ALA methyl ester have been extensively
studied in human colon carcinoma cells (WiDr).4–6
In recent years, a number of studies on HAL-mediated PDT
have been conducted. The improved penetration of HAL due
to its high lipophilicity was demonstrated by comparison of
distribution of ALA, whilst kinetics and intracellular localization
ofHAL-induced PpIXwere investigated in human and rat bladder
cancers in vivo and several human cancer cell lines.7–18 The
effect of illumination was examined in rat ovarian cancer and
porcine bladder mucosa.19,20 Moreover, tissue response to HAL-
PDT was monitored in rat bladder. The results revealed a clear
treatment response in vivo including decreased tissue oxygenation
Department of Cancer Research and Molecular Medicine, Norwegian
University of Science and Technology, N-7491, Trondheim, Norway.
E-mail: odrun.gederaas@ntnu.no; Fax: +4772576400; Tel: +4772573015
and PpIX photobleaching.21 Later, PpIX photobleaching was
proven to be a useful tool to predict the tissue response to HAL-
PDT.22 A clinical study comprising 24 patients demonstrated
that HAL-PDT was a non-invasive, repeatable procedure for
cervical intraepithelial neoplasia and no severe side effects were
encountered.23 Mechanisms of cell killing in PDT remain obscure,
but are most likely complex and apparently involve both caspase-
dependent and -independent apoptotic pathways.24–26
PDT results in a sequence of photochemical processes in pho-
tosensitized cells. Cellular antioxidant mechanisms are apparently
overloaded by high levels of reactive oxygen species (ROS) and
radicals. This leads toROS-inducedproteinmodiﬁcations anddys-
function, and eventually affects pathways resulting in cell death.27
The most thoroughly characterized oxidative modiﬁcations of
proteins subsequent to PDT are irreversible and non-enzymatic
carbonylation and oxidation of thiol groups.28,29 Magi et al. found
that a speciﬁc set of proteins, including structural proteins and
chaperones, were carbonylated and their results supported the
concept that oxidative damage to proteins was selectively induced
by PDT with Purpurin-18.30
The aim of the present study was to identify proteins with
altered expression levels and/or altered post-translational status
2 h subsequent to HAL-mediated PDT in rat bladder cancer
cells (AY-27), using 2D difference gel electrophoresis (2D-DIGE)
and mass spectrometry (MS). To detect protein carbonylation
and altered expression in less abundant proteins, carbonylated
proteins were labeled with 2,4-dinitrophenyl hydrazine (DNPH)
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
D
ow
nl
oa
de
d 
by
 R
SC
 In
te
rn
al
 o
n 
26
 M
ay
 2
01
1
Pu
bl
is
he
d 
on
 3
0 
M
ar
ch
 2
01
1 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| d
oi
:1
0.
10
39
/C
0P
P0
03
69
G
View Online
and immunoprecipitated with anti-DNP antibody prior to 2D-
GE and MS.31,32
2. Materials and methods
2.1 Cell culture and HAL-mediated light treatment
Rat bladder cancer cells (AY-27) were maintained in RPMI-
1640 culture medium (BioWhittaker) supplemented with 5% L-
glutamine, 1% penicillin/streptomycin, 0.1% fungizone and 10%
fetal bovine serum (FBS) in a humidiﬁed atmosphere of 95% air
and 5% CO2 at 37 ◦C.
About 3.5 ¥ 106 cells were seeded per Petri dish (diameter:
10 cm) and cultured for one day. Subsequent to wash cells with
PBS twice, RPMI-1640 culture medium (FBS-free) containing 10
mM HAL (PhotoCure AS, Norway) was added to cells and kept
in the dark for 3.5 h. The medium was then replaced with PBS,
and the cells were exposed to blue light (435 nm) for 35 s (0.45 J
cm-2, Lumi Source, PCI Biotech AS, Norway). Subsequent to 2 h
incubation in the dark in FBS-free medium, cells were harvested
by scraping in ice-cold PBS and centrifuged (450 g, 5 min, 4 ◦C).
Three groups of cell samples were analyzed in parallel: HAL;
cells incubated with HAL only. PDT; cells treated with blue
light after HAL incubation, and controls; without any treatment,
neither HAL incubation nor light exposure.
This protocol was chosen based on our earlier unpublished
results that the HAL-incubation time (3–3.5 h) gave a stable
production of PpIX inside the AY-27 cancer cells and light
treatment at the same experimental conditions led to about LD80
close to clinic target.
2.2 Protein extraction
Cell pellets were resuspended in 0.3¥ packed cell volume (PCV) of
buffer I (10 mM Tris-HCl pH 8.0, 200 mM KCl, 1 mM DTT, 1%
phosphatase inhibitor cocktail 1 and 2 (Sigma), 2% Complete
protease inhibitor cocktail (Roche) and mixed with a volume
of buffer II (10 mM Tris-HCl pH 8.0, 200 mM KCl, 2 mM
EDTA, 40% glycerol, 0.5% NP40, 1 mM DTT and phosphatase-
and protease inhibitors as above) corresponding to the combined
volumes of the pellet and buffer I. The mixture was incubated on
a roller (45 min, 4 ◦C) and sonicated (2 min, dark) using Branson
Soniﬁer250 (output 2, duty cycle 20). Subsequent to centrifugation
(10 min, 16100 g, 4 ◦C) supernatants (control, HAL and PDT)
were collected and protein concentrations were determined using
the Bio-Rad protein assay (BioRad Laboratories, USA).
2.3 Two dimensional difference gel electrophoresis (2D-DIGE)
Protein lysates (Control, HAL and PDT), 50 mg of each, were
diluted in 2¥ lysis buffer (7 M urea, 4% CHAPS, 30 mM Tris, 2 M
thiourea pH 8–8.5) and labelled with a speciﬁc CyDye (Cy2, Cy3
and Cy5, respectively), according to manufacturer’s instructions
(GE Healthcare). The reaction was quenched by adding 10 mM
lysine (1 ml) following incubation for 10 min on ice in the dark.
Each labelled protein sample was diluted 2-fold with 2¥ sample
buffer (7 M urea, 4% CHAPS, 30 mM Tris, 130 mM DTT) and
incubated on ice for 10 min. The three protein samples were mixed
together and 1¥ sample buffer was added to reach a ﬁnal volume
of 450 ml. Then, 1% IPG buffer pH 3–11 (GE Healthcare) was
added to the sample and rehydrated overnight into an IPGstrip
(pH 3–11, 24 cm). Isoelectric focusing (IEF) was carried out
according to the manufacturer’s instructions (GE Heathcare). For
the second dimension, strip was ﬁrst incubated with equilibration
stock buffer (50 M Tris-HCl pH 8.8, 6 M urea, 30% glycerol
and 2% SDS) containing 1% DTT for 15 min and then with
the equilibration stock buffer containing 2.5% iodoacetamide for
15min under agitation at room temperature. The equilibrated strip
was sealed on top of a 10% polyacrylamide gel using colorless
liquid agarose. The electrophoresis was run overnight using Ettan
DALT electrophoresis system (400 V, 20 mA, 2 W/gel, 20 ◦C).
Spots were visualized using the TyphoonTM Trio Imager (GE
Healthcare) at wavelengths of 520 nm, 580 nm and 620 nm. Images
were analyzed using DeCyderTM 2D software, which provides a
3D view of each protein spot. The spots are plotted as peaks
that represent directly both the distribution (peak area) of the
spot in the gel and its amount (peak volume). The relative peak
volumes of protein spots were used to calculate the volume ratio
of protein spots pairs (Cy3 and Cy5). Changes in volume ratio of
protein spots pairs were used to determine proteins differentially
expressed due to PDT treatment. Proteins of interest were then
selected using DeCyderTM 2D software and picked using Ettan
Spot Picker.
2.4 Two dimensional gel electrophoresis (2D-GE)
The HAL and PDT lysates (300 mg of each) were mixed together
and DeStreak rehydration solution (GE Healthcare) was added to
reach a ﬁnal volume of 450 ml. The IPGstrip (pH 3–11, 24 cm) was
rehydrated and protein separation by IEF and SDS-PAGE was
performed as described above.
After 2D-GE separation, the gel was stained with silver
according to the protocol established by Shevchenko33 with minor
modiﬁcations. Spots of interest were excised manually.
2.5 Protein identiﬁcation by mass spectrometry (MS)
Protein spots were in-gel digested with trypsin as described by
Shevchenko.33 Peptides were extracted from the gel and desalted
using StageTIP.34 The eluted peptides were mixed with HCCA (a-
cyano-4-hydroxycinnamic acid) matrix (7 g l-1 in 50% Acetonitrile,
50% ethanol) and loaded onto a MALDI-plate. Peptide mass
ﬁngerprints and MS/MS spectra were obtained using an Ultraﬂex
IIIMALDI-TOF/TOF instrument (BRUKERDaltonicsGmbH,
Germany). Protein identiﬁcation was performed by MSDB
database searches using the Mascot software (Matrix Science).
2.6 Carbonylated protein labeling with 2,4-dinitrophenyl
hydrazine (DNPH)
Protein lysates (1.5 mg each) were diluted (1 : 1) with 10% SDS
and incubated for 5 min prior to addition of an equal volume of
10 mM DNPH in 10% TFA and further incubation for 30 min
at room temperature under rotation. Reactions were stopped and
the products (DNP-protein) precipitated by adding 2 volumes of
20% ice-cold trichloroacetic acid (TCA) and incubation on ice for
45 min. Precipitated DNP-proteins were pelleted (20 min, 5900 g,
4 ◦C), and pellets were washed three times with acetone (5 min,
4500 g, 4 ◦C) and resuspended in 600 ml of a 1 : 1 mixture of buffer
I and II.
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Fig. 1 Proteomic map of HAL and PDT lysate samples of AY-27 cells. (A) Proteins under-expressed (green spots) or over-expressed (red spots) in the
PDT sample (HAL and light treatment) compared to control (only HAL treatment); (B) spot with lower Cy3/Cy5 ratio (DeCyder analysis) shown as
red in the proteomic map was up-regulated in the PDT sample. This spot together with other 3 spots to the right were identiﬁed as heat shock protein
60 kDa later by MS indicating pI-shift.; (C) Spot with higher Cy3/Cy5 ratio shown as green in the proteomic map was down-regulated in the PDT
sample.
2.7 Immunoprecipitation using anti-DNP antibody
Anti-DNP antibodies were covalently coupled to paramagnetic
Dynabeads protein A beads according to the manufacturer’s
protocol (Dynal). DNP-labelled protein samples were incubated
with crosslinked beads (150 ml) overnight at 4 ◦C with constant
agitation. The beads were washed three times with 10 mM Tris-
HCl (pH 8.3), 50 mM KCl (pH 8.3) and DNP-proteins eluted
with 1¥ Novex LDS loading buffer (13 ml, Invitrogen) and the
beads were further incubated overnight in 1¥ sample buffer
(117 ml). The combined eluates were then subjected to 2D-GE
using 7 cm IPGstrip (pH 3–11) and a 4–12% gradient NuPAGE
gel (Invitrogen). The gel was stained with Krypton protein stain
according to the manufacturer’s protocol (Pierce, USA) and the
spots were visualized using a Typhoon scanner (GE Healthcare).
3. Results and discussion
3.1 PDT treatment causes marked changes in protein expression
and apparent post-translational modiﬁcation status
Alterations in the apparent post-translationalmodiﬁcation (PTM)
status of proteins two hours subsequent to HAL alone or
HAL/PDT treatment of rat bladder cancer cells (AY-27) were
monitored in three parallel experiments using 2D-DIGE. Since
our primary objective was to identify altered migration of proteins
that could indicate differential PTM status, a Cy2-labelled internal
control was not included in the experiments. Nevertheless, a
marked difference in the overall expression level of several
proteins was evident from the Cy3/Cy5 ratios. Moreover, the
proteomic maps obtained from the parallel experiments were very
similar, indicating that the procedure is highly reproducible. A
representative proteomic map of HAL and PDT lysate samples is
shown in Fig. 1 (a), in which clear red spots represent up-regulated
proteins (Fig. 1, b) and clear green spots represent down-regulated
proteins (Fig. 1, c) in the PDT-treated cells as compared to cells
treated with HAL only. Yellow spots represent proteins expressed
at similar level in both samples. The 2D-DIGE image clearly
demonstrates that additional exposure of the HAL-treated cells
to blue light causes a striking change in the expression of some
proteins. Moreover, several proteins exhibited apparently different
migration in the 2D-gel, typically in the form of species having an
acidic pI-shift (Fig. 1, b). Such acidic shifts might be the result
of enzymatic modiﬁcations mediating gain of negative charge by,
for example, phosphorylation, or loss of positive charge by, for
example, acetylation. However, shifts towards the acidic side may
also result from non-enzymatic oxidative modiﬁcations, such as
oxidation of cysteine to cysteine sulfenic- or sulﬁnic acid.
In order to increase protein concentration and enhance protein
identiﬁcation in MS analysis, a 2D-GE was run with higher
amount of both HAL and PDT lysate samples (Fig. 2), and
proteins were excised from the silver-stained gel using the 2D-
DIGE gels as reference. A total of 40 proteins were identiﬁed
and assigned in the 2D-DIGE gel (Fig. 3). Among these, 15
proteinsweremarkedly up-/down-regulated or displayedmodiﬁed
post-translational status, as suggested by their altered migration.
As shown in Table 1, heterogeneous nuclear ribonucleoprotein
(hnRNP) L and pre-mRNA-processing factor 19 were markedly
up-regulated, while pyruvate kinase isozymes M1/M2, vimentin,
and tubulin alpha-1 chain were markedly down-regulated. The
remaining 10 proteins displayed acidic pI-shifts, as illustrated for
HSP60 (Fig. 1, b).
Apparent down-regulation of vimentin could be a consequence
of vimentin cross-linking resulting from carbonylation. This has
previously been observed in A549 cells subsequent to acrolein-
induced carbonylation,35 and would mediate a loss of vimentin
monomers in 1D-GE and 2D-GE gels. Interestingly, several of
the most abundant cytoskeletal and chaperone proteins such as
b-actin, protein disulﬁde-isomerase A6 and A3, HSP70/90 and
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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Table 1 Proteins and biological processes/pathways inAY-27 cells affected byHAL-mediated PDT, based on the 24 proteins subject to post-translational
modiﬁcation and differential expression, analyzed using Uniprot and PANTHER software (www.pantherdb.org)
Gene ID Name of protein Cellular location PDT responsea
Main molecular
function
Main biological
process/pathway Reference
P11980 pyruvate kinase isozymes
M1/M2
cytosol D carbohydrate kinase glycolysis/pyruvate
metabolism
P68370 tubulin alpha-1A chain microtubule D tubulin intracellular
protein trafﬁc, cell
structure and
motility, cell cycle,
developmental
process, etc.
30,37,38
P31000 vimentin nucleus, cytoplasm D structural protein ectoderm
development; cell
structure
35,39
Q5U1Y5 hnRNP Lb nucleus U ribosomal protein mRNA splicing
Q9JMJ4 pre-mRNA-processing
factor 19
nucleus U RNA-binding
protein
mRNA splicing
Q63081 protein disulﬁde
isomerase (PDI) A6
ER P other isomerase disulﬁde-isomerase
reaction
43,52
P11598 PDI A3 (p58) ER P isomerase disulﬁde-isomerase
reaction
43,52
P11884 aldehyde dehydrogenase mitochondria P dehydrogenase phenylethylamine
degradation
(carbon
metabolism)
Q66HD0 endoplasmin (GRP94,
HSP90)
ER P chaperone protein folding,
stress response
43–46,50,51
P63039 60kDa heat shock protein
(HSP60)
mitochondria P chaperonin protein folding 30,43–47,49–51
P10719 F1-ATPase beta chain mitochondria P other ion channel,
hydrogen
transporter, ATP
synthase; hydrolase
purine metabolism,
electron transport
(ATP synthesis)
Q6P136 hyou1 protein cytosol P chaperone stress response
P48721 stress-70 protein (GRP75) mitochondria P chaperone protein folding;
Stress response
(apoptosis
signaling pathway)
43–46
P14659 heat shock cognate
71kDa protein (HSP70)
cytosol, organelles P chaperone protein folding;
Stress response
(apoptosis
signaling pathway)
30,43–46,48–51
P60711 b-actin cytoplasm C, P, U actin and actin
related protein
transport;
cytokinesis; cell
structure, etc.
30–40
P15178 aspartyl-tRNA
synthetase
cytoplasm C, U aminoacyl-tRNA
synthetase
protein
biosynthesis
P02563 myosin-6 heavy chain cytoplasm C, U motor protein,
muscle protein
muscle contrac-
tion/development,
(Wnt signaling
pathway, cytokine
signaling pathway,
etc)
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Table 1 (Contd.)
Gene ID Name of protein Cellular location PDT responsea
Main molecular
function
Main biological
process/pathway Reference
P32089 tricarboxylate transport
protein (TCC)
mitochondria,
membrane
C, U mitochondrial
carrier protein
small molecule
transport
A7VJC2 hnRNP A2/B1 nucleus, cytoplasm C, U ribonucleoprotein mRNA splicing
P04256 hnRNP A1 nucleus, cytoplasm C, U ribonucleoprotein mRNA splicing,
mRNA transport
Q7TP52 carboxymethylene-
butenolidase homolog
cytoplasm C, U hydrolase; other
miscellaneous
function protein
carbohydrate
metabolism
Q5M7T9 threonine synthase-like 2 cytosol C, U synthase threonine
biosynthesis;
vitamin B6
metabolism
P54758 ephrin type-A receptor 6 membrane C, U tyrosine protein
kinase, receptor;
transferase
protein
phosphorylation;
cell proliferation
and differentiation;
receptor protein
tyrosine kinase
signaling pathway
Q06226 serum and glucocorticoid
-regulated kinase (sgk1)
ER, nucleus,
cytoplasm
C, D kinase activity Protein
phosphorylation;
Inhibition of
apoptosis; Other
homeostasis
activities and
intracellular
signaling cascade
a D: down-regulated; U: up-regulated; P: pI-shift; C: carbonylated. b hnRNP: heterogeneous nuclear ribonucleoprotein.
Fig. 2 Silver-stained gel. HAL and PDT lysate samples (300 mg of each)
of AY-27 cells were mixed and subjected to IEF in a 24 cm IPGstrip pH
3–11 and separated in a 10% polyacrylamide gel. Proteins selected from
the DIGE reference gel were excised from the silver stained gel for MS
identiﬁcation.
Grp75 all display marked acidic pI-shifts after HAL-mediated
PDT. It is tempting to speculate that these abundant proteins
may be quantitatively dominating targets for direct oxidative
attack within the cell during HAL-mediated PDT, and that the
observed pI-shifts may represent such covalent modiﬁcations that
are not reversed by the reducing conditions employed during 2D-
DIGE. Cysteine sulfonic acid is such an irreversible modiﬁcation,
whereas cysteine sulfenic acid and reaction products thereof
such as glutathioylations, are reversible,36 and would most likely
have been reverted during the procedure of two dimensional
gel-electrophoresis. Moreover, carbonylation should not mediate
pI shifts since they do not introduce charge differences in the
proteins. An alternative explanation would be that these proteins,
at least in part, are modiﬁed enzymatically as part of the oxidative
stress response. At least the protein disulﬁde isomerases, b-actin,
HSP70/90 may become phosphorylated as a consequence of
various forms of cellular stress, and for the chaperone group
of protein this apparently is part of a regulatory mechanism
modulating the substrate speciﬁcity.
Damage to several structural proteins induced by PDT was
previously reported using other cell lines and photosensitizers.
Moor et al. andLee et al. stated that cellular structures having high
sensitizer and a high oxygen concentration would be preferentially
damaged upon illumination.37,38 Belichenko et al. investigated
the role of vimentin in apoptosis after PDT with the silicon
phthalocyanine Pc4 in human Jurkat T cells and found that
the full-length vimentin confers resistance to nuclear apoptosis.39
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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Fig. 3 Mapping of 40 identiﬁed proteins in AY-27 cells (DIGE, 10% polyacrylamide gel). Protein spots of interest were picked from both 2D-DIGE gels
and silver stained 2D-GE gels and identiﬁed by MALDI-TOF/TOF (Ultraﬂex III, BRUKER Daltonics GmbH, Germany).
Later, Tsaytler et al. concluded that more structural proteins
were oxidatively modiﬁed in human epidermoid carcinoma cells
A431 after Pc4-PDT,40 and Magi et al. described that tubulin a-1
chain and b-actin were modiﬁed via carbonylation after PDT with
Purpurin-18 in human HL60 cells.30
It has been demonstrated that some cell lines can respond
to photodynamic damage by initiating a rescue response41,42 to
induce expression of stress proteins containing a number of heat
shock proteins (HSPs) and glucose-regulated proteins (GRPs).43–46
The contribution by HSP60 increased the resistance to Photofrin-
mediated PDT in human colon cancer cell line (HT29),47 while
HSP70 was demonstrated to inhibit apoptosis mediated by PDT
with either dihematoporphyrin ether or Purpurin-18 in human
leukemia cells (HL60).48 Elevated expression of both HSP60 and
HSP70 after ALA-PDT was observed in several human cell lines
by Yanase et al.,49 and these proteins were carbonylated during
Purpurin-18mediated PDT, as reported byMagi et al.30 Moreover,
it has been demonstrated that the amounts of HSP60, HSP70
and GRP94 (endoplasmin, HSP90) increased at the cell surface,
contributing to enhanced immune responses in mouse tumor
cells (SCCVII) after Photofrin-mediated PDT.50,51 Our results
show that several rescue/stress proteins were modiﬁed in the
rat cell line AY-27 after HAL-PDT, including HSP60, HSP70,
GRP94,GRP75andhyou1protein. These proteins have important
chaperone functions in the cell and apparently may shield the
cells from oxidative damage. Interestingly, Magi et al.30 hypoth-
esized that cellular chaperones may actually bind to oxidized
proteins and that a protein-protein radical transfer can occur
from oxidized proteins to chaperones. Thus, certain chaperones
trying to reduce the toxic effect of oxidative stress are themselves
oxidized.
Among proteins involved in energy metabolism, pI-shift was
observed for hyou1 protein and F1-ATPase beta chain. Addi-
tionally, pyruvate kinase isozymes M1/M2 were shown to be
down-regulated. These modiﬁcations might contribute to energy
insufﬁciency and cell death by inhibiting the hypoxia responses.
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Fig. 4 Mapping of carbonylated proteins of AY-27 cells 2 h subsequent to HAL-mediated PDT. Nine up-regulated proteins are shown in PDT sample
(right) and one down-regulated is shown inControl sample (left). Each sample (1.5mg)was labeledwith 10mMDNPH in 10%TFAand immunoprecipited
with 150 ml cross-linked protein A beads with anti-DNP antibodies before 2D-GE separation. Protein spots of interest were excised from krypton-gels
and 10 carbonylated proteins were identiﬁed by MALDI-TOF/TOF.
Moreover, the modiﬁcations on the rescue/stress proteins might
lose their protective effect against oxidative stress triggering the
suicide mechanism after PDT.
Three proteins associated with Ca2+ signaling pathways were
shown to be affected by ALA-PDT,43,52 including calreticulin
precursor, protein disulﬁde isomerase (p55) and protein disulﬁde
isomerase A3 (p58).43 In our study, although protein p58, p55 and
calcineurin subunit B have been identiﬁed, only p58was conﬁrmed
to be modiﬁed by showing a pI-shift. More experiments are
required to identify possible HAL-PDT effects on this signaling
pathway.
3.2 Detection of carbonylated proteins
The most widely used marker for oxidative damage to proteins
is the presence of carbonyl groups. Carbonyls can be introduced
into proteins either by direct oxidation of Pro, Arg, Lys, and Thr
side chains or by Michael addition reactions with products of
lipid peroxidation or glycol-oxidation. Elevation in the total level
of protein carbonyls has been documented after PDT, but the
identities of the proteins modiﬁed by carbonylation or other types
of oxidation remain largely incompletely understood. Since car-
bonylation, in contrast to oxidation of cysteine to cysteine sulfonic
or sulﬁnic acid, do not mediate a change in pI, control and PDT
samples were derivatized with DNPH and immunoprecipitated
using an anti-DNP antibody prior to separation by 2D-GE. By
using this experimental outline we were able to identify 9 proteins
with increased carbonylation and, surprisingly, one protein with
reduced carbonylation (Fig. 4).
According to our results, b-actin was conﬁrmed to be carbony-
lated after HAL-PDT, in agreement with results after PDT with
Purpurin-18 in HL60.30 However, carbonylation is apparently
not the only modiﬁcation induced in b-actin by HAL-PDT.
The pI-shift towards the acidic side indicates that alternative
oxidations such as cysteine sulﬁnic acid, or secondary enzymatic
modiﬁcations such as phosphorylation, may be present.
Moreover, protein hnRNP A1 and hnRNP A2/B1 were con-
ﬁrmed to be up-regulated and oxidized. Together with pre-mRNA
processing factor 19 and hnRNP L (Table 1), four up-regulated
proteins in our results are related to DNA-repair, pre-mRNA
processing and mRNA splicing. These results may suggest that
transcription, translation or stability may have been increased
in response to protein and DNA damages under oxidative stress
induced by HAL-mediated PDT.
Interestingly, mitochondrial tricarboxylate carrier protein
(TCC) and serum and glucocorticoid-regulated kinase 1 (sgk1)
were found to display altered expression or modiﬁcation after
PDT. Both of them are supposed to play a key role in oxidative
stress conditions in rat brain.53,54 Our results demonstrate that
both proteins were carbonylated. TCC was up-regulated, while
sgk1 was down-regulated already at 2 h post-PDT.
3.3 Proteins, pathways and processes affected by HAL-PDT
ROS-inducedmodiﬁcationsmay changeprotein functions, thereby
affecting biological processes and signaling pathways.27 A total
of more than 200 post-translational modiﬁcations have been
identiﬁed.55 Furthermore, increasing evidence suggests that many
proteins carry multiple and distinct modiﬁcations. These may in
some cases antagonize or synergize each other, with important
biological consequences.55 Thus, the PANTHERclassiﬁcation sys-
tem was used to gain information of potential affected biological
processes afterHAL-PDT.Clearly, the complex responses indicate
that no single mechanism can be responsible for the effects of
HAL-PDT (Table 1).
In AY-27 cells the endogenous photosensitizer PpIX is syn-
thesized and accumulated in mitochondria, and moves to
other membrane-rich organelles when a certain concentration
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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is reached.1 Classiﬁcation of proteins by cellular localization
(Table 1) demonstrates that the majority of the modiﬁed proteins
by HAL-PDT were from mitochondria, ER and membranes.
However, in the study of Pc4-PDT,40 the majority of affected
proteins were cytosolic, likely reﬂecting a somewhat different
cellular targeting of PpIX and Pc4.56 So far, nuclear localization
of PpIX has not been observed. Nevertheless, several cytoplasmic
and nuclear proteins were shown to be affected in our study,
likely caused by indirect oxidation or intracellular translocation
subsequent to HAL-mediated PDT.
4. Conclusions
Our results demonstrate that a number of proteins in AY-27
cells are differentially expressed or chemically or enzymatically
modiﬁed after HAL-mediated PDT, thus most likely affecting
important processes, such as cell motility, energy metabolism,
and signaling pathways for survival and cell death. The results
support previous studies employing other photosensitizers,30,40 in
that numerous cellular pathways are likely to be affected by PDT.
The majority of proteins identiﬁed subsequent to 2D-DIGE dis-
played acidic pI-shifts, indicating altered phosphorylation status
or oxidative thiol modiﬁcations. Notably, these proteins mainly
belong to the mitochondrial/ER molecular chaperones and stress
proteins, indicating that these cellular compartments are major
targets for HAL-mediated PDT. These results have extended our
understanding of the clinic effects associated with ALA-PDT, and
may pave the way for potential new adjuvant drugs. Our further
studies are, however, warranted to elucidate to what degree these
modiﬁcations are associated with the apoptotic signaling events
induced by HAL-PDT. By better understanding mechanisms of
PDT-mediated cytotoxicity in AY-27 bladder cancer cells, we aim
at improving efﬁcacy of PDT in the in vivo rat model21 and
ultimately in treatment of human bladder. This may also pave
the way for targeted use of other treatment modalities, such as
siRNA and photochemical internalization (PCI).57
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